1
|
Fernández T, Plana T, Tardón L, Marco O, Navarro L, Bartrés C, Colom J, Goikolea JM, Cavero M, Pacchiarotti I, Lens S, Forns X, Martín-Santos R, Mariño Z. Low risk of viral hepatitis amongst patients with severe mental disorders. Liver Int 2023; 43:1204-1212. [PMID: 37041668 DOI: 10.1111/liv.15569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/06/2022] [Revised: 02/15/2023] [Accepted: 03/22/2023] [Indexed: 04/13/2023]
Abstract
BACKGROUND AND AIMS Patients with severe mental disorders (SMD) have been classically considered as a particularly high-risk population for bloodborne virus infections. We performed a systematic screening of hepatitis B and C virus among the population with SMD in the area of influence of Hospital Clínic (Barcelona) in order to evaluate the real prevalence of these infections and achieve HCV microelimination in this subpopulation. METHODS We screened two cohorts for anti-HCV and HBsAg: Cohort A (hospitalized patients with SMD, done systematically) and Cohort B (outpatients, mental health centre-CSMA, done voluntarily). Risk factors and socio-demographic variables were collected. In positive cases, telematic review was activated by Hepatology, calculation of FIB-4 and prescription of direct-acting agents (DAA) in HCV or follow-up in HBV. RESULTS In Cohort A, 404 patients were screened. 3 HBV patients were detected (0.7%). In all of them, there was a history of drug use. 12 anti-HCV positive patients were detected (3%); 8 of them had a history of drug use. Among the HCV positive, only 2 patients were viraemic (received DAA, both achieving SVR) as most of them (n = 6) had already been cured with DAA. In cohort B, 305 patients were screened, after 542 (64% of the target population) declined to participate. No cases of HCV or HBV were detected. CONCLUSIONS HCV/HBV prevalence among SMD population with no history of drug use does not seem to be different from the general population. These data may be of interest for defining health policies.
Collapse
Affiliation(s)
- Tábatha Fernández
- Psychiatry and Psychology Department, Hospital Clínic de Barcelona, Barcelona, Spain
| | - Teresa Plana
- Psychiatry and Psychology Department, Hospital Clínic de Barcelona, Barcelona, Spain
- Liver Unit, Hospital Clínic Barcelona, Barcelona, Spain
| | - Laia Tardón
- Psychiatry and Psychology Department, Hospital Clínic de Barcelona, Barcelona, Spain
| | - Oriol Marco
- Psychiatry and Psychology Department, Hospital Clínic de Barcelona, Barcelona, Spain
| | - Lourdes Navarro
- Psychiatry and Psychology Department, Hospital Clínic de Barcelona, Barcelona, Spain
| | | | - Joan Colom
- Public Health Agency of Catalonia, Health Department, General Subdirection on Prevention, Control and Care on Addictions, HIV, STI and Viral Hepatitis, Barcelona, Spain
| | - José Manuel Goikolea
- Psychiatry and Psychology Department, Hospital Clínic de Barcelona, Barcelona, Spain
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERsam), Madrid, Spain
- Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain
| | - Myriam Cavero
- Psychiatry and Psychology Department, Hospital Clínic de Barcelona, Barcelona, Spain
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERsam), Madrid, Spain
- Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain
| | - Isabella Pacchiarotti
- Psychiatry and Psychology Department, Hospital Clínic de Barcelona, Barcelona, Spain
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERsam), Madrid, Spain
- Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain
| | - Sabela Lens
- Liver Unit, Hospital Clínic Barcelona, Barcelona, Spain
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Hepáticas (CIBERehd), Madrid, Spain
| | - Xavier Forns
- Liver Unit, Hospital Clínic Barcelona, Barcelona, Spain
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Hepáticas (CIBERehd), Madrid, Spain
| | - Rocío Martín-Santos
- Psychiatry and Psychology Department, Hospital Clínic de Barcelona, Barcelona, Spain
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERsam), Madrid, Spain
- Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain
| | - Zoe Mariño
- Liver Unit, Hospital Clínic Barcelona, Barcelona, Spain
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Hepáticas (CIBERehd), Madrid, Spain
| |
Collapse
|
2
|
Navinés R, Olivé V, Fonseca F, Martín-Santos R. Work stress and resident burnout, before and during the COVID-19 pandemia: An up-date. Med Clin (Engl Ed) 2021; 157:130-140. [PMID: 35005240 PMCID: PMC8721440 DOI: 10.1016/j.medcle.2021.04.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Accepted: 04/06/2021] [Indexed: 02/05/2023]
Affiliation(s)
- Ricard Navinés
- Unidad Funcional de Psiquiatría, Departamento de Medicina, Instituto de Neurociencias, Universidad de Barcelona (UB), Barcelona, Spain.,Societat Catalana de Psiquiatria i Salut Mental (SCPiSM), Barcelona, Spain
| | - Victoria Olivé
- Unidad Funcional de Psiquiatría, Departamento de Medicina, Instituto de Neurociencias, Universidad de Barcelona (UB), Barcelona, Spain.,Servicio de Prevención de Riesgos Laborales, Hospital Clínic, Barcelona, Spain
| | - Francina Fonseca
- Societat Catalana de Psiquiatria i Salut Mental (SCPiSM), Barcelona, Spain.,Grupo de Investigación en Adicciones, Instituto de Investigación Médica Hospital del Mar (IMIM), Universidad Autònoma de Barcelona, Instituto de Neuropsiquiatría y Adicciones (INAD), Red de Trastornos Adictivos (RediTA), Barcelona, Spain
| | - Rocío Martín-Santos
- Grupo de Investigación en Vulnerabilidad, Psicopatología y Género, Servicio de Psiquiatría y Psicología, Programa de Atención al Personal Sanitario, Hospital Clínic, IDIBAPS, CIBERSAM, Barcelona, Spain.,Unidad Funcional de Psiquiatría, Departamento de Medicina, Instituto de Neurociencias, Universidad de Barcelona (UB), Barcelona, Spain.,Societat Catalana de Psiquiatria i Salut Mental (SCPiSM), Barcelona, Spain
| |
Collapse
|
3
|
Blanco-Hinojo L, Pujol J, Macià D, Martínez-Vilavella G, Martín-Santos R, Pérez-Sola V, Deus J. Mapping the Synchronization Effect of Gamma-Aminobutyric Acid Inhibition on the Cerebral Cortex Using Magnetic Resonance Imaging. Brain Connect 2021; 11:393-403. [PMID: 33797949 DOI: 10.1089/brain.2020.0844] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background: Functional magnetic resonance imaging (fMRI) of spontaneous brain activity permits the identification of functional networks on the basis of region synchrony. The functional coupling between the elements of a neural system increases during brain activation. However, neural synchronization may also be the effect of inhibitory gamma-aminobutyric acid (GABA) neurons in states of brain inhibition such as sleep or pharmacological sedation. We investigated the effects of an oral dose of alprazolam, a classical benzodiazepine known to enhance inhibitory neurotransmission, using recently developed measures of local functional connectivity. Methods: In a randomized, double-blind, placebo-controlled, crossover design, 32 non-treatment-seeking individuals with social anxiety underwent two identical resting-state fMRI sessions on separate days after receiving 0.75 mg of alprazolam and placebo. Functional connectivity maps of the cerebral cortex were generated by using multidistance functional connectivity measures defined within iso-distant local areas. Results: Relative to placebo, increased intracortical functional connectivity was observed in the alprazolam condition in visual, auditory, and sensorimotor cortices, and in areas of sensory integration such as the posterior insula and orbitofrontal cortex (OFC). Alprazolam significantly reduced subjective arousal compared with placebo, and the change was associated with variations in multidistance functional connectivity measures in the OFC. Discussion: In conclusion, we report evidence that alprazolam significantly modifies neural activity coupling at rest in the form of functional connectivity enhancement within the cerebral cortex. The effect of alprazolam was particularly evident in the cortical sensory system, which would further suggest a differentiated effect of GABA inhibition on sensory processing.
Collapse
Affiliation(s)
- Laura Blanco-Hinojo
- MRI Research Unit, Department of Radiology, Hospital del Mar, Barcelona, Spain.,Centro Investigación Biomédica en Red de Salud Mental, CIBERSAM, Barcelona, Spain
| | - Jesus Pujol
- MRI Research Unit, Department of Radiology, Hospital del Mar, Barcelona, Spain.,Centro Investigación Biomédica en Red de Salud Mental, CIBERSAM, Barcelona, Spain
| | - Dídac Macià
- MRI Research Unit, Department of Radiology, Hospital del Mar, Barcelona, Spain
| | | | - Rocío Martín-Santos
- Department of Psychiatry and Psychology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Department of Medicine, Faculty of Medicine, and Institute of Neuroscience, University of Barcelona (UB), Barcelona, Spain
| | - Víctor Pérez-Sola
- Centro Investigación Biomédica en Red de Salud Mental, CIBERSAM, Barcelona, Spain.,Institute of Neuropsychiatry and Addictions, Hospital del Mar-IMIM, Barcelona, Spain.,Department of Psychiatry, Autonomous University of Barcelona, Barcelona, Spain
| | - Joan Deus
- MRI Research Unit, Department of Radiology, Hospital del Mar, Barcelona, Spain.,Department of Psychobiology and Methodology in Health Sciences, Autonomous University of Barcelona, Barcelona, Spain
| |
Collapse
|
4
|
Mariño Z, Rodríguez-Tajes S, Bartrés C, Nácar L, Lens S, Navinés R, Cavero M, Londoño MC, Sastre L, Pocurull A, Dafieno A, Martín-Santos R, Forns X. Improvement of sexuality after hepatitis C cure with direct acting antivirals. Liver Int 2020; 40:2972-2977. [PMID: 33025664 DOI: 10.1111/liv.14689] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/02/2020] [Revised: 08/14/2020] [Accepted: 09/29/2020] [Indexed: 12/17/2022]
Abstract
Despite rarely assessed, sexuality is a relevant domain in Quality of Life. We prospectively evaluated the impact of direct-acting antiviral therapy on sexuality in a cohort of 186 patients with chronic hepatitis C (HCV). Sexual dysfunction was assessed by validated scales CSFQ-14/CSFQ-VAS at baseline and one year after treatment finalization. Median age was 55 years and 87% had mild liver disease. Basal prevalence of sexual dysfunction (62%) and fear of HCV transmission (25%) were high. After HCV cure, both sexual dysfunction prevalence and CSFQ-VAS improved (P = .058 and P < .01, respectively), and fear of HCV transmission dropped to 16% (P = .02). These changes were especially relevant in young men (<55), where sexual dysfunction decreased from 48.6% to 29.7% (P = .04) and among non-depressed patients in whom sexual dysfunction decreased from 54.6% to 47% (P < .01). Age and major depression remained as independent factors of sexual dysfunction persistence after HCV cure. Our data suggest that HCV eradication is associated with an improvement in sexuality, in those patients without depression.
Collapse
Affiliation(s)
- Zoe Mariño
- Liver Unit, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS) and Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Spain
| | - Sergio Rodríguez-Tajes
- Liver Unit, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS) and Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Spain
| | - Concepció Bartrés
- Liver Unit, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS) and Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Spain
| | - Loreto Nácar
- Liver Unit, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS) and Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Spain.,Psychiatry and Psycology Department, Hospital Clínic Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Neurociencias, University of Barcelona, Barcelona, Spain
| | - Sabela Lens
- Liver Unit, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS) and Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Spain
| | - Ricard Navinés
- Psychiatry and Psycology Department, Hospital Clínic Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Neurociencias, University of Barcelona, Barcelona, Spain
| | - Myriam Cavero
- Psychiatry and Psycology Department, Hospital Clínic Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Neurociencias, University of Barcelona, Barcelona, Spain
| | - María C Londoño
- Liver Unit, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS) and Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Spain
| | - Lydia Sastre
- Liver Unit, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS) and Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Spain
| | - Anna Pocurull
- Liver Unit, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS) and Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Spain
| | - Angella Dafieno
- Liver Unit, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS) and Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Spain
| | - Rocío Martín-Santos
- Psychiatry and Psycology Department, Hospital Clínic Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Neurociencias, University of Barcelona, Barcelona, Spain
| | - Xavier Forns
- Liver Unit, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS) and Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Spain
| |
Collapse
|
5
|
Gutierrez-Zotes A, Gallardo-Pujol D, Labad J, Martín-Santos R, García-Esteve L, Gelabert E, Jover M, Guillamat R, Mayoral F, Gornemann I, Canellas F, Gratacós M, Guitart M, Roca M, Costas J, Ivorra JL, Navinés R, de Diego Y, Vilella E, Sanjuan J. Factor Structure of the Spanish Version of the Edinburgh Postnatal Depression Scale. Actas Esp Psiquiatr 2018; 46:174-182. [PMID: 30338774] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 09/01/2018] [Accepted: 09/01/2018] [Indexed: 06/08/2023]
Abstract
INTRODUCTION The Edinburgh Postnatal Depression Scale (EPDS) is considered the gold standard in screening for postpartum depression. Although the Spanish version has been widely used, its factorial structure has not yet been studied . METHODS A total of 1,204 women completed the EPDS 32 weeks after delivery. To avoid multiple testing, we split the sample into two halves, randomly drawing two subsamples of 602 participants each. We conducted exploratory factor analysis (EFA), followed by an oblimin rotation with the first sub-sample. Confirmatory factor analysis (CFA) was conducted using a Weighted Least Squares Means and Variance (WLSMV) estimation of the data. We explored different solutions between two and four factors. We compared the factors between two groups with depression and non-depression (evaluated with the Diagnostic Interview for Genetic Studies (DIGS) for the DSM-IV). RESULTS The EFA indicated a three-factor model consisting of anxiety, depression and anhedonia. The results of the CFA confirmed the three-factor model (χ2=99.203, p<0.001; RMSEA=0.06, 90% CI=0.04/0.07, CFI=0.87 and TLI=0.82). Women with depression in the first 32 weeks obtained higher scores for anxiety, depression and anhedonia dimensions (p<0.001). CONCLUSIONS This is the first study of confirmatory analysis with the Spanish version of EPDS in a large sample of women without psychiatric care during pregnancy. A three-factor model consisting of anxiety, depression and anhedonia was used. Women with depression had a higher score in the three dimensions of the EPDS.
Collapse
Affiliation(s)
- Alfonso Gutierrez-Zotes
- Hospital Universitari Institut Pere Mata, IISPV, Universitat Rovira i Virgili. CIBERSAM. Reus, España
| | - David Gallardo-Pujol
- Facultat de Psicología, Universitat de Barcelona, Instituto de Neurociencias, Universidad de Barcelona
| | - Javier Labad
- Departmento de Salud Mental, Parc Taulí Hospital Universitario, Instituto de Investigación Sanitaria Parc Taulí (I3PT), Universidad Autónoma de Barcelona. CIBERSAM. Sabadell, España
| | - Rocío Martín-Santos
- Departamento de Psiquiatría, Instituto de Neurociencias, Hospital Clinic, IDIBAPS, CIBERSAM y Departamento de Psiquiatría y Psicobiología Clínica, Universidad de Barcelona, Barcelona, España Programa de Neurociencias, IMIM-Parc de Salut Mar, Universidad Autónoma de Barcelona, RTA, Barcelona, España
| | - Luisa García-Esteve
- Departamento de Psiquiatría, Instituto de Neurociencias, Hospital Clinic, IDIBAPS, CIBERSAM y Departamento de Psiquiatría y Psicobiología Clínica, Universidad de Barcelona, Barcelona, España
| | - Estel Gelabert
- Programa de Neurociencias, IMIM-Parc de Salut Mar, Universidad Autónoma de Barcelona, RTA, Barcelona, España Departamento de Psicología Clínica y de la Salud, Universidad Autónoma de Barcelona, Bellaterra, España
| | - Manuel Jover
- Hospital Clinic, Universidad de Valencia, CIBERSAM, Valencia, España
| | | | - Fermín Mayoral
- UGC Salud Mental. Hospital Regional Universitario de Málaga, España
| | - Isolde Gornemann
- UGC Salud Mental. Hospital Regional Universitario de Málaga, España
| | | | - Mónica Gratacós
- Centro de Regulación Genómica (CRG) y UPF, Barcelona, España, Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Barcelona, España
| | - Miriam Guitart
- Departmento de Salud Mental, Parc Taulí Hospital Universitario, Instituto de Investigación Sanitaria Parc Taulí (I3PT), Universidad Autónoma de Barcelona. CIBERSAM. Sabadell, España
| | - Miguel Roca
- Institut Universitari d'Investigació en Ciències de la Salut, RediAPP, Palma de Mallorca, España
| | - Javier Costas
- Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS) Servizo Galego de Saúde (SERGAS), Complexo Hospitalario Universitario de Santiago (CHUS). España
| | - Jose Luis Ivorra
- Hospital Clinic, Universidad de Valencia, CIBERSAM, Valencia, España
| | - Ricard Navinés
- Departamento de Psiquiatría, Instituto de Neurociencias, Hospital Clinic, IDIBAPS, CIBERSAM y Departamento de Psiquiatría y Psicobiología Clínica, Universidad de Barcelona, Barcelona, España Programa de Neurociencias, IMIM-Parc de Salut Mar, Universidad Autónoma de Barcelona, RTA, Barcelona, España
| | - Yolanda de Diego
- Instituto de Investigación Biomédica de Málaga (IBIMA). Hospital Universitario Regional de Malaga. UGC Salud Mental, España
| | - Elisabet Vilella
- Hospital Universitari Institut Pere Mata, IISPV, Universitat Rovira i Virgili. CIBERSAM. Reus, España
| | - Julio Sanjuan
- Hospital Clinic, Universidad de Valencia, CIBERSAM, Valencia, España
| |
Collapse
|
6
|
Macià D, Pujol J, Blanco-Hinojo L, Martínez-Vilavella G, Martín-Santos R, Deus J. Characterization of the Spatial Structure of Local Functional Connectivity Using Multidistance Average Correlation Measures. Brain Connect 2018; 8:276-287. [DOI: 10.1089/brain.2017.0575] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Affiliation(s)
- Dídac Macià
- MRI Research Unit, Department of Radiology, Hospital del Mar, Barcelona, Spain
| | - Jesus Pujol
- MRI Research Unit, Department of Radiology, Hospital del Mar, Barcelona, Spain
- Centro Investigación Biomédica en Red de Salud Mental, CIBERSAM G21, Barcelona, Spain
| | - Laura Blanco-Hinojo
- MRI Research Unit, Department of Radiology, Hospital del Mar, Barcelona, Spain
- Centro Investigación Biomédica en Red de Salud Mental, CIBERSAM G21, Barcelona, Spain
| | | | - Rocío Martín-Santos
- Department of Psychiatry and Psychology, Hospital Clínic, Institut d'Investigació Biomédica August Pi I Sunyer, CIBERSAM G25, Barcelona, Spain
| | - Joan Deus
- MRI Research Unit, Department of Radiology, Hospital del Mar, Barcelona, Spain
- Department of Clinical and Health Psychology, Autonomous University of Barcelona, Barcelona, Spain
| |
Collapse
|
7
|
Batalla A, Lorenzetti V, Chye Y, Yücel M, Soriano-Mas C, Bhattacharyya S, Torrens M, Crippa JAS, Martín-Santos R. The Influence of DAT1, COMT, and BDNF Genetic Polymorphisms on Total and Subregional Hippocampal Volumes in Early Onset Heavy Cannabis Users. Cannabis Cannabinoid Res 2018; 3:1-10. [PMID: 29404409 PMCID: PMC5797324 DOI: 10.1089/can.2017.0021] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Introduction: Hippocampal neuroanatomy is affected by genetic variations in dopaminergic candidate genes and environmental insults, such as early onset of chronic cannabis exposure. Here, we examine how hippocampal total and subregional volumes are affected by cannabis use and functional polymorphisms of dopamine-relevant genes, including the catechol-O-methyltransferase (COMT), dopamine transporter (DAT1), and the brain-derived neurotrophic factor (BDNF) genes. Material and Methods: We manually traced total hippocampal volumes and automatically segmented hippocampal subregions using high-resolution MRI images, and performed COMT, DAT1, and BDNF genotyping in 59 male Caucasian young adults aged 18–30 years. These included 30 chronic cannabis users with early-onset (regular use at <16 years) and 29 age-, education-, and intelligence-matched controls. Results: Cannabis use and dopaminergic gene polymorphism had both distinct and interactive effects on the hippocampus. We found emerging alterations of hippocampal total and specific subregional volumes in cannabis users relative to controls (i.e., CA1, CA2/3, and CA4), and associations between cannabis use levels and total and specific subregional volumes. Furthermore, total hippocampal volume and the fissure subregion were affected by cannabis×DAT1 polymorphism (i.e., 9/9R and in 10/10R alleles), reflecting high and low levels of dopamine availability. Conclusion: These findings suggest that cannabis exposure alters the normal relationship between DAT1 polymorphism and the anatomy of total and subregional hippocampal volumes, and that specific hippocampal subregions may be particularly affected.
Collapse
Affiliation(s)
- Albert Batalla
- Department of Psychiatry, Clinical Institute of Neuroscience, Hospital Clínic, IDIBAPS, CIBERSAM and Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Barcelona, Spain.,Department of Psychiatry, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.,Nijmegen Institute for Scientist-Practitioners in Addiction (NISPA), Radboud University, Nijmegen, The Netherlands
| | - Valentina Lorenzetti
- School of Psychological Sciences, Institute of Psychology Health and Society, The University of Liverpool, Liverpool, United Kingdom.,Laboratory for Brain and Mental Health, Monash Institute of Cognitive and Clinical Neurosciences and School of Psychological Sciences, Monash University, Clayton, VIC, Australia
| | - Yann Chye
- Laboratory for Brain and Mental Health, Monash Institute of Cognitive and Clinical Neurosciences and School of Psychological Sciences, Monash University, Clayton, VIC, Australia
| | - Murat Yücel
- Laboratory for Brain and Mental Health, Monash Institute of Cognitive and Clinical Neurosciences and School of Psychological Sciences, Monash University, Clayton, VIC, Australia
| | - Carles Soriano-Mas
- Department of Psychiatry, Bellvitge University Hospital-IDIBELL, CIBERSAM G-17, and Department of Psychobiology and Methodology in Health Sciences, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Sagnik Bhattacharyya
- Department of Psychosis Studies, King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom
| | - Marta Torrens
- Institute of Neuropsychiatry and Addictions, Hospital del Mar, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Psychiatric Department of Universitat Autònoma de Barcelona, Barcelona, Spain
| | - José A S Crippa
- Department of Neuroscience and Behavior, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.,Instituto Nacional de Ciência e Tecnologia Translacional em Medicina Translational Medicine (INCT-TM), National Council for Scientific and Technological Development, São Paulo, Brazil
| | - Rocío Martín-Santos
- Department of Psychiatry, Clinical Institute of Neuroscience, Hospital Clínic, IDIBAPS, CIBERSAM and Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Barcelona, Spain.,Institute of Neuropsychiatry and Addictions, Hospital del Mar, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Psychiatric Department of Universitat Autònoma de Barcelona, Barcelona, Spain.,Department of Neuroscience and Behavior, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.,Instituto Nacional de Ciência e Tecnologia Translacional em Medicina Translational Medicine (INCT-TM), National Council for Scientific and Technological Development, São Paulo, Brazil
| |
Collapse
|
8
|
Blanco-Hinojo L, Pujol J, Harrison BJ, Macià D, Batalla A, Nogué S, Torrens M, Farré M, Deus J, Martín-Santos R. Attenuated frontal and sensory inputs to the basal ganglia in cannabis users. Addict Biol 2017; 22:1036-1047. [PMID: 26934839 DOI: 10.1111/adb.12370] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2015] [Revised: 11/30/2015] [Accepted: 01/07/2016] [Indexed: 12/18/2022]
Abstract
Heavy cannabis use is associated with reduced motivation. The basal ganglia, central in the motivation system, have the brain's highest cannabinoid receptor density. The frontal lobe is functionally coupled to the basal ganglia via segregated frontal-subcortical circuits conveying information from internal, self-generated activity. The basal ganglia, however, receive additional influence from the sensory system to further modulate purposeful behaviors according to the context. We postulated that cannabis use would impact functional connectivity between the basal ganglia and both internal (frontal cortex) and external (sensory cortices) sources of influence. Resting-state functional connectivity was measured in 28 chronic cannabis users and 29 controls. Selected behavioral tests included reaction time, verbal fluency and exposition to affective pictures. Assessments were repeated after one month of abstinence. Cannabis exposure was associated with (1) attenuation of the positive correlation between the striatum and areas pertaining to the 'limbic' frontal-basal ganglia circuit, and (2) attenuation of the negative correlation between the striatum and the fusiform gyrus, which is critical in recognizing significant visual features. Connectivity alterations were associated with lower arousal in response to affective pictures. Functional connectivity changes had a tendency to normalize after abstinence. The results overall indicate that frontal and sensory inputs to the basal ganglia are attenuated after chronic exposure to cannabis. This effect is consistent with the common behavioral consequences of chronic cannabis use concerning diminished responsiveness to both internal and external motivation signals. Such an impairment of the fine-tuning in the motivation system notably reverts after abstinence.
Collapse
Affiliation(s)
| | - Jesus Pujol
- MRI Research Unit; Hospital del Mar; Barcelona Spain
- Centro Investigación Biomédica en Red de Salud Mental; CIBERSAM G21; Barcelona Spain
| | - Ben J Harrison
- Melbourne Neuropsychiatry Centre, Department of Psychiatry; The University of Melbourne; Melbourne Australia
| | - Dídac Macià
- MRI Research Unit; Hospital del Mar; Barcelona Spain
| | - Albert Batalla
- Department of Psychiatry and Psychology; Hospital Clínic, Institut d'Investigació Biomédica August Pi I Sunyer (IDIBAPS), CIBERSAM G25; Barcelona Spain
- Nijmegen Institute for Scientist-Practitioners in Addiction; Nijmegen Netherlands
| | - Santiago Nogué
- Section of Clinical Toxicology, Emergency Service, Hospital Clínic, IDIBAPS; University of Barcelona; Barcelona Spain
| | - Marta Torrens
- Human Pharmacology and Clinical Neurosciences; Institute of Neuropsychiatry and Addiction, Hospital del Mar Medical Research Institute; Barcelona Spain
- School of Medicine, Autonomous University of Barcelona; Red de Trastornos Adictivos (RETIC); Barcelona Spain
| | - Magí Farré
- Human Pharmacology and Clinical Neurosciences; Institute of Neuropsychiatry and Addiction, Hospital del Mar Medical Research Institute; Barcelona Spain
- School of Medicine, Autonomous University of Barcelona; Red de Trastornos Adictivos (RETIC); Barcelona Spain
| | - Joan Deus
- MRI Research Unit; Hospital del Mar; Barcelona Spain
- Department of Clinical and Health Psychology; Autonomous University of Barcelona; Barcelona Spain
| | - Rocío Martín-Santos
- Department of Psychiatry and Psychology; Hospital Clínic, Institut d'Investigació Biomédica August Pi I Sunyer (IDIBAPS), CIBERSAM G25; Barcelona Spain
- Department of Psychiatry and Clinical Psychobiology; University of Barcelona; Barcelona Spain
| |
Collapse
|
9
|
Gutiérrez-Zotes A, Labad J, Martín-Santos R, García-Esteve L, Gelabert E, Jover M, Guillamat R, Mayoral F, Gornemann I, Canellas F, Gratacós M, Guitart M, Roca M, Costas J, Ivorra JL, Navinés R, de Diego-Otero Y, Vilella E, Sanjuan J. Coping strategies for postpartum depression: a multi-centric study of 1626 women. Arch Womens Ment Health 2016; 19:455-61. [PMID: 26399872 DOI: 10.1007/s00737-015-0581-5] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2015] [Accepted: 09/14/2015] [Indexed: 01/27/2023]
Abstract
The transition to motherhood is stressful as it requires several important changes in family dynamics, finances, and working life, along with physical and psychological adjustments. This study aimed at determining whether some forms of coping might predict postpartum depressive symptomatology. A total of 1626 pregnant women participated in a multi-centric longitudinal study. Different evaluations were performed 8 and 32 weeks after delivery. Depression was assessed using the Edinburgh Postnatal Depression Scale (EPDS) and the structured Diagnostic Interview for Genetic Studies (DIGS). The brief Coping Orientation for Problem Experiences (COPE) scale was used to measure coping strategies 2-3 days postpartum. Some coping strategies differentiate between women with and without postpartum depression. A logistic regression analysis was used to explore the relationships between the predictors of coping strategies and major depression (according to DSM-IV criteria). In this model, the predictor variables during the first 32 weeks were self-distraction (OR 1.18, 95 % CI 1.04-1.33), substance use (OR 0.58, 95 % CI 0.35-0.97), and self-blame (OR 1.18, 95 % CI 1.04-1.34). In healthy women with no psychiatric history, some passive coping strategies, both cognitive and behavioral, are predictors of depressive symptoms and postpartum depression and help differentiate between patients with and without depression.
Collapse
Affiliation(s)
- Alfonso Gutiérrez-Zotes
- Clínica Psiquiátrica Universitaria - Hospital Universitari Institut Pere Mata, Research Department, IISPV, Universitat Rovira i Virgili, CIBERSAM, Ctra. De l'Institut Pere Mata s/n, 43206, Reus, Spain.
| | - Javier Labad
- Clínica Psiquiátrica Universitaria - Hospital Universitari Institut Pere Mata, Research Department, IISPV, Universitat Rovira i Virgili, CIBERSAM, Ctra. De l'Institut Pere Mata s/n, 43206, Reus, Spain
| | - Rocío Martín-Santos
- Psychiatry Department, Neuroscience Institute, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.,Neuroscience Program, IMIM-Parc de Salut Mar, Autonoma University of Barcelona, RTA, Barcelona, Spain.,Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Barcelona, Spain
| | - Luisa García-Esteve
- Psychiatry Department, Neuroscience Institute, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.,Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Barcelona, Spain
| | - Estel Gelabert
- Neuroscience Program, IMIM-Parc de Salut Mar, Autonoma University of Barcelona, RTA, Barcelona, Spain.,Department of Clinical and Health Psychology, Autonoma University of Barcelona, Bellaterra, Spain
| | - Manuel Jover
- Hospital Clinic, University of Valencia, CIBERSAM, Valencia, Spain
| | - Roser Guillamat
- Corporación Sanitaria Parc Taulí, Sabadell, Autonoma University of Barcelona, Barcelona, Spain
| | - Fermín Mayoral
- Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Complejo Hospitalario de Málaga, Universidad de Málaga, Málaga, Spain
| | - Isolde Gornemann
- Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Complejo Hospitalario de Málaga, Universidad de Málaga, Málaga, Spain
| | | | - Mónica Gratacós
- Centre for Genomic Regulation (CRG) and UPF, Barcelona, Spain.,Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
| | - Montserrat Guitart
- Corporación Sanitaria Parc Taulí, Sabadell, Autonoma University of Barcelona, Barcelona, Spain
| | - Miguel Roca
- Institut Universitari d'Investigació en Ciències de la Salut, RediAPP, Palma de Mallorca, Spain
| | - Javier Costas
- Complexo Hospitalario Universitario de Santiago (CHUS), Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS) Servizo Galego de Saúde (SERGAS), Reus, Spain
| | - Jose Luis Ivorra
- Hospital Clinic, University of Valencia, CIBERSAM, Valencia, Spain
| | - Ricard Navinés
- Psychiatry Department, Neuroscience Institute, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.,Neuroscience Program, IMIM-Parc de Salut Mar, Autonoma University of Barcelona, RTA, Barcelona, Spain.,Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Barcelona, Spain
| | - Yolanda de Diego-Otero
- Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Complejo Hospitalario de Málaga, Universidad de Málaga, Málaga, Spain
| | - Elisabet Vilella
- Clínica Psiquiátrica Universitaria - Hospital Universitari Institut Pere Mata, Research Department, IISPV, Universitat Rovira i Virgili, CIBERSAM, Ctra. De l'Institut Pere Mata s/n, 43206, Reus, Spain
| | - Julio Sanjuan
- Hospital Clinic, University of Valencia, CIBERSAM, Valencia, Spain
| |
Collapse
|
10
|
Udina M, Navinés R, Egmond E, Oriolo G, Langohr K, Gimenez D, Valdés M, Gómez-Gil E, Grande I, Gratacós M, Kapczinski F, Artigas F, Vieta E, Solà R, Martín-Santos R. Glucocorticoid Receptors, Brain-Derived Neurotrophic Factor, Serotonin and Dopamine Neurotransmission are Associated with Interferon-Induced Depression. Int J Neuropsychopharmacol 2016; 19:pyv135. [PMID: 26721949 PMCID: PMC4851270 DOI: 10.1093/ijnp/pyv135] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2015] [Revised: 11/24/2015] [Accepted: 12/11/2015] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND The role of inflammation in mood disorders has received increased attention. There is substantial evidence that cytokine therapies, such as interferon alpha (IFN-alpha), can induce depressive symptoms. Indeed, proinflammatory cytokines change brain function in several ways, such as altering neurotransmitters, the glucocorticoid axis, and apoptotic mechanisms. This study aimed to evaluate the impact on mood of initiating IFN-alpha and ribavirin treatment in a cohort of patients with chronic hepatitis C. We investigated clinical, personality, and functional genetic variants associated with cytokine-induced depression. METHODS We recruited 344 Caucasian outpatients with chronic hepatitis C, initiating IFN-alpha and ribavirin therapy. All patients were euthymic at baseline according to DSM-IV-R criteria. Patients were assessed at baseline and 4, 12, 24, and 48 weeks after treatment initiation using the Patient Health Questionnaire (PHQ), the Hospital Anxiety and Depression Scale (HADS), and the Temperament and Character Inventory (TCI). We genotyped several functional polymorphisms of interleukin-28 (IL28B), indoleamine 2,3-dioxygenase (IDO-1), serotonin receptor-1A (HTR1A), catechol-O-methyl transferase (COMT), glucocorticoid receptors (GCR1 and GCR2), brain-derived neurotrophic factor (BDNF), and FK506 binding protein 5 (FKBP5) genes. A survival analysis was performed, and the Cox proportional hazards model was used for the multivariate analysis. RESULTS The cumulative incidence of depression was 0.35 at week 24 and 0.46 at week 48. The genotypic distributions were in Hardy-Weinberg equilibrium. Older age (p = 0.018, hazard ratio [HR] per 5 years = 1.21), presence of depression history (p = 0.0001, HR = 2.38), and subthreshold depressive symptoms at baseline (p = 0.005, HR = 1.13) increased the risk of IFN-induced depression. So too did TCI personality traits, with high scores on fatigability (p = 0.0037, HR = 1.17), impulsiveness (p = 0.0200 HR = 1.14), disorderliness (p = 0.0339, HR = 1.11), and low scores on extravagance (p = 0.0040, HR = 0.85). An interaction between HTR1A and COMT genes was found. Patients carrying the G allele of HTR1A plus the Met substitution of the COMT polymorphism had a greater risk for depression during antiviral treatment (HR = 3.83) than patients with the CC (HTR1A) and Met allele (COMT) genotypes. Patients carrying the HTR1A CC genotype and the COMT Val/Val genotype (HR = 3.25) had a higher risk of depression than patients with the G allele (HTR1A) and the Val/Val genotype. Moreover, functional variants of the GCR1 (GG genotype: p = 0.0436, HR = 1.88) and BDNF genes (Val/Val genotype: p = 0.0453, HR = 0.55) were associated with depression. CONCLUSIONS The results of the study support the theory that IFN-induced depression is associated with a complex pathophysiological background, including serotonergic and dopaminergic neurotransmission as well as glucocorticoid and neurotrophic factors. These findings may help to improve the management of patients on antiviral treatment and broaden our understanding of the pathogenesis of mood disorders.
Collapse
MESH Headings
- Adult
- Antiviral Agents/therapeutic use
- Brain-Derived Neurotrophic Factor/genetics
- Catechol O-Methyltransferase/genetics
- Depression/chemically induced
- Depression/epidemiology
- Depression/genetics
- Depression/immunology
- Female
- Genetic Predisposition to Disease
- Hepatitis C, Chronic/drug therapy
- Hepatitis C, Chronic/epidemiology
- Hepatitis C, Chronic/genetics
- Hepatitis C, Chronic/psychology
- Humans
- Incidence
- Indoleamine-Pyrrole 2,3,-Dioxygenase/genetics
- Interferon-alpha/adverse effects
- Interferon-alpha/therapeutic use
- Interferons
- Interleukins/genetics
- Male
- Middle Aged
- Polymorphism, Single Nucleotide
- Prospective Studies
- Receptor, Serotonin, 5-HT1A/genetics
- Receptors, Glucocorticoid/genetics
- Ribavirin/therapeutic use
- Tacrolimus Binding Proteins/genetics
- Treatment Outcome
- White People/genetics
Collapse
Affiliation(s)
- M Udina
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - R Navinés
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - E Egmond
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - G Oriolo
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - K Langohr
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - D Gimenez
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - M Valdés
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - E Gómez-Gil
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - I Grande
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - M Gratacós
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - F Kapczinski
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - F Artigas
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - E Vieta
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - R Solà
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - R Martín-Santos
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| |
Collapse
|
11
|
Navinés R, Martín-Santos R, Olivé V, Valdés M. [Work-related stress: Implications for physical and mental health]. Med Clin (Barc) 2016; 146:359-66. [PMID: 26806767 DOI: 10.1016/j.medcli.2015.11.023] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2015] [Revised: 11/12/2015] [Accepted: 11/23/2015] [Indexed: 10/22/2022]
Affiliation(s)
- Ricard Navinés
- Servei de Psiquiatria i Psicologia, Hospital Clínic, Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, España.
| | - Rocío Martín-Santos
- Servei de Psiquiatria i Psicologia, Hospital Clínic, Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, España
| | - Victòria Olivé
- Servei de Prevenció de Riscos Laborals, Hospital Clínic, Barcelona, España
| | - Manuel Valdés
- Servei de Psiquiatria i Psicologia, Hospital Clínic, Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, España
| |
Collapse
|
12
|
Gutiérrez-Zotes A, Labad J, Martín-Santos R, García-Esteve L, Gelabert E, Jover M, Guillamat R, Mayoral F, Gornemann I, Canellas F, Gratacós M, Guitart M, Roca M, Costas J, Luis Ivorra J, Navinés R, de Diego-Otero Y, Vilella E, Sanjuan J. Coping strategies and postpartum depressive symptoms: A structural equation modelling approach. Eur Psychiatry 2015; 30:701-8. [PMID: 26141375 DOI: 10.1016/j.eurpsy.2015.06.001] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/27/2014] [Revised: 05/26/2015] [Accepted: 06/01/2015] [Indexed: 10/23/2022] Open
Abstract
BACKGROUND Variables such as the mother's personality, social support, coping strategies and stressful events have been described as risk factors for postpartum depression. Structural Equation Modelling (SEM) analysis was used to examine whether neuroticism, perceived social support, perceived life events, and coping strategies are associated with postpartum depressive symptoms at the 8th and 32nd weeks. METHODS A total of 1626 pregnant women participated in a longitudinal study. Different evaluations were performed 8 and 32weeks after delivery. Several measures were used: the Edinburgh Postnatal Depression Scale (EPDS), the Diagnostic Interview for Genetic Studies (DIGS), the Eysenck Personality Questionnaire (EPQ-RS), the St. Paul Ramsey life events scale and the Duke-UNC Functional Social Support Questionnaire. The brief COPE scale was used to measure coping strategies. SEM analysis was conducted for all women and in those women with a clinical diagnosis of postpartum depression. RESULTS Passive coping strategies were associated with postpartum depressive symptoms at both visits (8th and 32nd weeks). Neuroticism was associated with more passive coping strategies and less active coping strategies. Neuroticism and life stress were positively correlated, and social support was negatively correlated with life stress and neuroticism. CONCLUSIONS Early identification of potential risk for symptomatology of depression postpartum should include assessment of neuroticism, life events, social support and coping strategies.
Collapse
Affiliation(s)
- A Gutiérrez-Zotes
- Hospital Universitari Institut Pere Mata, IISPV, Universitat Rovira i Virgili, CIBERSAM, Reus, Spain.
| | - J Labad
- Hospital Universitari Institut Pere Mata, IISPV, Universitat Rovira i Virgili, CIBERSAM, Reus, Spain
| | - R Martín-Santos
- Psychiatry Department, Neuroscience Institute, Hospital Clinic, IDIBAPS, CIBERSAM and Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Barcelona, Spain; Neuroscience Program, IMIM-Parc de Salut Mar, Autonomous University of Barcelona, RTA, Barcelona, Spain
| | - L García-Esteve
- Psychiatry Department, Neuroscience Institute, Hospital Clinic, IDIBAPS, CIBERSAM and Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Barcelona, Spain
| | - E Gelabert
- Neuroscience Program, IMIM-Parc de Salut Mar, Autonomous University of Barcelona, RTA, Barcelona, Spain; Department of Clinical and Health Psychology, Autonomous University of Barcelona, Bellaterra, Barcelona, Spain
| | - M Jover
- Hospital Clínico, University of Valencia, CIBERSAM, Valencia, Spain
| | - R Guillamat
- Corporación Sanitaria Parc Taulí, Sabadell, Autonomous University of Barcelona, Barcelona, Spain
| | - F Mayoral
- Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Complejo Hospitalario de Málaga, Universidad de Málaga, Spain
| | - I Gornemann
- Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Complejo Hospitalario de Málaga, Universidad de Málaga, Spain
| | - F Canellas
- Hospital de Son Dureta, Palma de Mallorca, Spain
| | - M Gratacós
- Centre for Genomic Regulation (CRG) and UPF, Barcelona, Spain; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
| | - M Guitart
- Corporación Sanitaria Parc Taulí, Sabadell, Autonomous University of Barcelona, Barcelona, Spain
| | - M Roca
- Institut Universitari d'Investigació en Ciències de la Salut, RediAPP, Palma de Mallorca, Spain
| | - J Costas
- Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS) Servizo Galego de Saúde (SERGAS), Complexo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela, Spain
| | - J Luis Ivorra
- Hospital Clínico, University of Valencia, CIBERSAM, Valencia, Spain
| | - R Navinés
- Psychiatry Department, Neuroscience Institute, Hospital Clinic, IDIBAPS, CIBERSAM and Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Barcelona, Spain; Neuroscience Program, IMIM-Parc de Salut Mar, Autonomous University of Barcelona, RTA, Barcelona, Spain
| | - Y de Diego-Otero
- Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Complejo Hospitalario de Málaga, Universidad de Málaga, Spain
| | - E Vilella
- Hospital Universitari Institut Pere Mata, IISPV, Universitat Rovira i Virgili, CIBERSAM, Reus, Spain
| | - J Sanjuan
- Hospital Clínico, University of Valencia, CIBERSAM, Valencia, Spain
| |
Collapse
|
13
|
Martín-Santos R, Binelli C, Subirá S, Muñiz A, Navinés R, Crippa J. New Evidence of Heterogeneity in Social Anxiety Disorder: Defining Two Qualitatively Different Personality Profiles Taking into Account Clinical, Environmental and Genetic Factors. Eur Psychiatry 2015. [DOI: 10.1016/s0924-9338(15)31898-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
14
|
Binelli C, Muñiz A, Sanches S, Ortiz A, Navines R, Egmond E, Udina M, Batalla A, López-Sola C, Crippa JA, Subirà S, Martín-Santos R. New evidence of heterogeneity in social anxiety disorder: defining two qualitatively different personality profiles taking into account clinical, environmental and genetic factors. Eur Psychiatry 2014; 30:160-5. [PMID: 25499444 DOI: 10.1016/j.eurpsy.2014.09.418] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/10/2014] [Revised: 08/22/2014] [Accepted: 09/21/2014] [Indexed: 01/04/2023] Open
Abstract
PURPOSE To study qualitatively different subgroups of social anxiety disorder (SAD) based on harm avoidance (HA) and novelty seeking (NS) dimensions. METHOD One hundred and forty-two university students with SAD (SCID-DSM-IV) were included in the study. The temperament dimensions HA and NS from the Cloninger's Temperament and Character Inventory were subjected to cluster analysis to identify meaningful subgroups. The identified subgroups were compared for sociodemographics, SAD severity, substance use, history of suicide and self-harm attempts, early life events, and two serotonin transporter gene polymorphisms (5-HTTLPR and STin2.VNTR). RESULTS Two subgroups of SAD were identified by cluster analysis: a larger (61% of the sample) inhibited subgroup of subjects with "high-HA/low-NS", and a smaller (39%) atypical impulsive subgroup with high-moderate HA and NS. The two groups did not differ in social anxiety severity, but did differ in history of lifetime impulsive-related-problems. History of suicide attempts and self-harm were as twice as frequent in the impulsive subgroup. Significant differences were observed in the pattern of substance misuse. Whereas subjects in the inhibited subgroup showed a greater use of alcohol (P=0.002), subjects in the impulsive subgroup showed a greater use of substances with a high-sensation-seeking profile (P<0.001). The STin2.VNTR genotype frequency showed an inverse distribution between subgroups (P=0.005). CONCLUSIONS Our study provides further evidence for the presence of qualitatively different SAD subgroups and the propensity of a subset of people with SAD to exhibit impulsive, high-risk behaviors.
Collapse
Affiliation(s)
- C Binelli
- Service of Psychiatry and Psychology, Hospital Clínic, IDIBAPS, CIBERSAM, Barcelona, Spain; Department of Clinical and Health Psychology, Autonomous University of Barcelona, Bellaterra, Spain
| | - A Muñiz
- Service of Psychiatry and Psychology, Hospital Clínic, IDIBAPS, CIBERSAM, Barcelona, Spain; Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Barcelona, Spain
| | - S Sanches
- Service of Psychiatry and Psychology, Hospital Clínic, IDIBAPS, CIBERSAM, Barcelona, Spain; Department of Neuroscience and Cognitive Behavior, Hospital das Clinicas, Ribeirao Preto, University of Sao Paulo, Sao Paulo, Brazil
| | - A Ortiz
- Service of Psychiatry and Psychology, Hospital Clínic, IDIBAPS, CIBERSAM, Barcelona, Spain; Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Barcelona, Spain
| | - R Navines
- Service of Psychiatry and Psychology, Hospital Clínic, IDIBAPS, CIBERSAM, Barcelona, Spain; Human Pharmacology and Clinical Neurosciences Research Group, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain
| | - E Egmond
- Service of Psychiatry and Psychology, Hospital Clínic, IDIBAPS, CIBERSAM, Barcelona, Spain; Department of Clinical and Health Psychology, Autonomous University of Barcelona, Bellaterra, Spain
| | - M Udina
- Service of Psychiatry and Psychology, Hospital Clínic, IDIBAPS, CIBERSAM, Barcelona, Spain
| | - A Batalla
- Service of Psychiatry and Psychology, Hospital Clínic, IDIBAPS, CIBERSAM, Barcelona, Spain; Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Barcelona, Spain
| | - C López-Sola
- Department of Clinical and Health Psychology, Autonomous University of Barcelona, Bellaterra, Spain
| | - J A Crippa
- Department of Neuroscience and Cognitive Behavior, Hospital das Clinicas, Ribeirao Preto, University of Sao Paulo, Sao Paulo, Brazil
| | - S Subirà
- Department of Clinical and Health Psychology, Autonomous University of Barcelona, Bellaterra, Spain
| | - R Martín-Santos
- Service of Psychiatry and Psychology, Hospital Clínic, IDIBAPS, CIBERSAM, Barcelona, Spain; Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Barcelona, Spain.
| |
Collapse
|
15
|
Sanches SB, Osório FL, Louzada-Junior P, Moraes D, Crippa JAS, Martín-Santos R. Association between joint hypermobility and anxiety in Brazilian university students: gender-related differences. J Psychosom Res 2014; 77:558-61. [PMID: 25219975 DOI: 10.1016/j.jpsychores.2014.08.016] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/15/2014] [Revised: 08/23/2014] [Accepted: 08/26/2014] [Indexed: 11/29/2022]
Abstract
INTRODUCTION Anxiety disorders may be associated with several non-psychiatric disorders. Current literature has been investigating the association between anxiety and joint hypermobility (JHM), with special interest in non-articular symptoms that may be related to autonomic dysfunction. This study investigated the association between anxiety and JHM in a sample of Brazilian university students. METHODS Data were cross-sectionally collected in two Brazilian universities (N=2600). Participants completed three validated self-rating anxiety scales: Beck Anxiety Inventory (BAI), Social Phobia Inventory (SPIN) and the brief-version of SPIN (Mini-SPIN). They also answered the self-rating screening questionnaire for JHM: the Five-part Questionnaire for Identifying Hypermobility. RESULTS Hypermobile women showed significantly higher scores in all the anxiety scales, when compared with men: BAI total score (t=3.77; p<0.001), its four subscales, SPIN score (t=2.71; p<0.007) and Mini-SPIN (t=2.58; p<0.01). Among BAI subscales, the autonomic subscale was shown to be more significantly (t=3.89; p<0.001) associated with joint hypermobility in women. CONCLUSIONS The results of the present study support earlier evidence on the relationship between anxiety and JHM in women, showing specific gender-related features in this field. It also directs attention to non-articular symptoms that may be enrolled in this association.
Collapse
Affiliation(s)
- S B Sanches
- Neuroscience and Behavior Department, Faculty of Medicine of Ribeirão Preto - University of São Paulo, Brazil; Departments of Psychiatry and Psychology, Hospital Clínic, University of Barcelona, Institut d'Investigació Biomèdiques August Pi I Sunyer (IDIBAPS), CIBERSAM, Barcelona, Catalonia, Spain.
| | - F L Osório
- Neuroscience and Behavior Department, Faculty of Medicine of Ribeirão Preto - University of São Paulo, Brazil
| | - P Louzada-Junior
- Division of Clinical Immunology, Center for Research in Inflammatory Disease, Faculty of Medicine of Ribeirão Preto - University of São Paulo, Brazil
| | - D Moraes
- Division of Clinical Immunology, Center for Research in Inflammatory Disease, Faculty of Medicine of Ribeirão Preto - University of São Paulo, Brazil
| | - J A S Crippa
- Neuroscience and Behavior Department, Faculty of Medicine of Ribeirão Preto - University of São Paulo, Brazil
| | - R Martín-Santos
- Departments of Psychiatry and Psychology, Hospital Clínic, University of Barcelona, Institut d'Investigació Biomèdiques August Pi I Sunyer (IDIBAPS), CIBERSAM, Barcelona, Catalonia, Spain
| |
Collapse
|
16
|
Binelli C, Subirà S, Batalla A, Muñiz A, Sugranyés G, Crippa J, Farré M, Pérez-Jurado L, Martín-Santos R. Common and distinct neural correlates of facial emotion processing in social anxiety disorder and Williams syndrome: A systematic review and voxel-based meta-analysis of functional resonance imaging studies. Neuropsychologia 2014; 64:205-17. [DOI: 10.1016/j.neuropsychologia.2014.08.027] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2014] [Revised: 08/01/2014] [Accepted: 08/16/2014] [Indexed: 12/27/2022]
|
17
|
Udina M, Hidalgo D, Navinés R, Forns X, Solà R, Farré M, Capuron L, Vieta E, Martín-Santos R. Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry 2014; 75:e1113-21. [PMID: 25373120 DOI: 10.4088/jcp.13r08800] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/17/2013] [Accepted: 02/28/2014] [Indexed: 10/24/2022]
Abstract
OBJECTIVE To assess the utility of prophylactic administration of antidepressants in preventing a major depressive episode during antiviral treatment for chronic hepatitis C. DATA SOURCES A computerized literature search was conducted in MEDLINE, PsycINFO, EMBASE, the Cochrane Library, and ClinicalTrials.gov to locate articles published in any language from the earliest available online year until October 2012, using the following phrase and Boolean logic algorithm: "hepatitis and c and (interferon-alpha OR peginterferon OR (pegylated and interferon)) and (depression OR mood) and (prevention OR prophylactic OR prophylaxis OR antidepressant)." STUDY SELECTION Double-blind, randomized, placebo-controlled trials using antidepressants prophylactically before starting antiviral therapy for chronic hepatitis C were included. At baseline, none of the patients in the trials presented depression (DSM-IV-TR criteria). Using keywords and cross-referenced bibliographies, 144 studies were identified and examined in depth. 137 articles were rejected because inclusion criteria were not met. Finally, 7 studies were included. DATA EXTRACTION Data were extracted independently by 2 investigators. The primary outcome measure was the onset of a major depressive episode during the antiviral treatment. Depressive symptoms, other side effects, and sustained virologic response were also examined. A full review and meta-analysis were performed. Odds ratios (ORs), mean differences, and estimated numbers needed to treat (NNTs) with 95% confidence intervals (CIs) were calculated. RESULTS 591 patients were randomly assigned to antiviral treatment and another intervention: escitalopram (n = 197), paroxetine (n = 42), citalopram (n = 53), or placebo (n = 299). Selective serotonin reuptake inhibitors (SSRIs), as a group, reduced the incidence of a major depressive episode during antiviral treatment (OR = 0.53; 95% CI, 0.33 to 0.84). The NNT was 12 (95% CI, 7.0 to 37.9). SSRIs reduced depressive symptoms at 24 weeks of treatment (mean difference -2.18; 95% CI, -4.25 to -0.10). With regard to side effects, only dizziness was associated with administration of antidepressants (OR = 2.65; 95% CI, 1.46 to 4.80). There were no differences in sustained virologic response (OR = 1.22; 95% CI, 0.58 to 2.57). CONCLUSIONS Administration of SSRIs before starting antiviral treatment reduces the incidence of interferon-induced depression, with a relatively moderate prophylactic impact and good tolerability.
Collapse
Affiliation(s)
- Marc Udina
- Department of Psychiatry and Psychology, Hospital Clínic, IDIBAPS, CIBERSAM; and Department of Psychiatry and Clinical Psychobiology, Universitat de Barcelona, Catalonia
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Sanches SB, Oliveira GM, Osório FL, Crippa JAS, Martín-Santos R. Hypermobility and joint hypermobility syndrome in Brazilian students and teachers of ballet dance. Rheumatol Int 2014; 35:741-7. [PMID: 25218649 DOI: 10.1007/s00296-014-3127-7] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2014] [Accepted: 09/03/2014] [Indexed: 11/29/2022]
Abstract
The current literature has been discussing the risks and benefits of joint hypermobility (JHM) for careers in ballet This study aimed to evaluate the prevalence of JHM and joint hypermobility syndrome (JHS) in a group of ballet teachers and students, looking both at aspects related to the flexibility required to dance, as at the risk of injuries when hypermobility is associated with other symptoms, in the case of JHS. We evaluated ballet teachers and ballet students, with age ranging from 18 to 40 years. All participants completed identification and sociodemographic questionnaires and underwent a physical examination. JHM was assessed using the Beighton score with goniometry. Symptoms of JHS were evaluated according to the Brighton criteria. Final sample consisted of 77 participants, being 44 ballet students and 33 ballet teachers. The prevalence of JHM in the sample as a whole was 58 %. Teachers and students had no significant differences regarding the prevalence of JHM (p = 0.74) (OR 1.21; 95 % CI 0.48-3.07). However, the prevalence of JHS was significantly different (p = 0.04) between students (16 %) and teachers (36 %). Teachers were three times more likely than student to have JHS (OR 3.02; 95 % CI 1.03-8.85). Teachers and students also presented differences in the frequency of specific items of Beighton score and Brighton criteria. These data provide elements to discuss the relationship between hypermobility, ballet technique and selection for dance, suggesting that dancers with JHS could find in ballet teaching an alternative to maintain professional activity with dance, while remaining protected from the higher risk of injury that professional dancers may be exposed to.
Collapse
Affiliation(s)
- S B Sanches
- Department of Neuroscience and Behavior, Hospital das Clínicas, Ribeirão Preto Medical School, University of São Paulo, Terceiro Andar, Av. Bandeirantes, 3900, Ribeirão Preto, São Paulo, 14049-800, Brazil,
| | | | | | | | | |
Collapse
|
19
|
Pujol J, Macià D, Blanco-Hinojo L, Martínez-Vilavella G, Sunyer J, de la Torre R, Caixàs A, Martín-Santos R, Deus J, Harrison BJ. Does motion-related brain functional connectivity reflect both artifacts and genuine neural activity? Neuroimage 2014; 101:87-95. [PMID: 24999036 DOI: 10.1016/j.neuroimage.2014.06.065] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2014] [Revised: 06/18/2014] [Accepted: 06/27/2014] [Indexed: 11/15/2022] Open
Abstract
Imaging research on functional connectivity is uniquely contributing to characterize the functional organization of the human brain. Functional connectivity measurements, however, may be significantly influenced by head motion that occurs during image acquisition. The identification of how motion influences such measurements is therefore highly relevant to the interpretation of a study's results. We have mapped the effect of head motion on functional connectivity in six different populations representing a wide range of potential influences of motion on functional connectivity. Group-level voxel-wise maps of the correlation between a summary head motion measurement and functional connectivity degree were estimated in 80 young adults, 71 children, 53 older adults, 20 patients with Down syndrome, 24 with Prader-Willi syndrome and 20 with Williams syndrome. In highly compliant young adults, motion correlated with functional connectivity measurements showing a system-specific anatomy involving the sensorimotor cortex, visual areas and default mode network. Further characterization was strongly indicative of these changes expressing genuine neural activity related to motion, as opposed to pure motion artifact. In the populations with larger head motion, results were more indicative of widespread artifacts, but showing notably distinct spatial distribution patterns. Group-level regression of motion effects was efficient in removing both generalized changes and changes putatively related to neural activity. Overall, this study endorses a relatively simple approach for mapping distinct effects of head motion on functional connectivity. Importantly, our findings support the intriguing hypothesis that a component of motion-related changes may reflect system-specific neural activity.
Collapse
Affiliation(s)
- Jesus Pujol
- MRI Research Unit, CRC Mar, Hospital del Mar, Barcelona, Spain; Centro Investigación Biomédica en Red de Salud Mental, CIBERSAM G21, Barcelona, Spain.
| | - Dídac Macià
- MRI Research Unit, CRC Mar, Hospital del Mar, Barcelona, Spain
| | - Laura Blanco-Hinojo
- MRI Research Unit, CRC Mar, Hospital del Mar, Barcelona, Spain; Human Pharmacology and Clinical Neurosciences, Hospital del Mar Medical Research Institute, Barcelona, Spain
| | | | - Jordi Sunyer
- Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Universitat Pompeu Fabra (UFP), Barcelona, Spain
| | - Rafael de la Torre
- Human Pharmacology and Clinical Neurosciences, Hospital del Mar Medical Research Institute, Barcelona, Spain; CIBER-Fisiopatología de la Obesidad y Nutrición (CIBEROBN), S. de Compostela, Spain
| | - Assumpta Caixàs
- Diabetes Endocrinology and Nutrition Department, Hospital de Sabadell, Institut Universitari Parc Taulí, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Rocío Martín-Santos
- Department of Psychiatry and Clinical Psychobiology, Clinical Institute of Neuroscience, Hospital Clínic, CIBERSAM, University of Barcelona, Barcelona, Spain
| | - Joan Deus
- MRI Research Unit, CRC Mar, Hospital del Mar, Barcelona, Spain; Department of Clinical and Health Psychology, Autonomous University of Barcelona, Barcelona, Spain
| | - Ben J Harrison
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne, Melbourne, Australia
| |
Collapse
|
20
|
Batalla A, Soriano-Mas C, López-Solà M, Torrens M, Crippa JA, Bhattacharyya S, Blanco-Hinojo L, Fagundo AB, Harrison BJ, Nogué S, de la Torre R, Farré M, Pujol J, Martín-Santos R. Modulation of brain structure by catechol-O-methyltransferase Val(158) Met polymorphism in chronic cannabis users. Addict Biol 2014; 19:722-32. [PMID: 23311613 DOI: 10.1111/adb.12027] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Neuroimaging studies have shown that chronic consumption of cannabis may result in alterations in brain morphology. Recent work focusing on the relationship between brain structure and the catechol-O-methyltransferase (COMT) gene polymorphism suggests that functional COMT variants may affect brain volume in healthy individuals and in schizophrenia patients. We measured the influence of COMT genotype on the volume of four key regions: the prefrontal cortex, neostriatum (caudate-putamen), anterior cingulate cortex and hippocampus-amygdala complex, in chronic early-onset cannabis users and healthy control subjects. We selected 29 chronic cannabis users who began using cannabis before 16 years of age and matched them to 28 healthy volunteers in terms of age, educational level and IQ. Participants were male, Caucasians aged between 18 and 30 years. All were assessed by a structured psychiatric interview (PRISM) to exclude any lifetime Axis-I disorder according to Diagnostic and Statistical Manual for Mental Disorders-Fourth Edition. COMT genotyping was performed and structural magnetic resonance imaging data was analyzed by voxel-based morphometry. The results showed that the COMT polymorphism influenced the volume of the bilateral ventral caudate nucleus in both groups, but in an opposite direction: more copies of val allele led to lesser volume in chronic cannabis users and more volume in controls. The opposite pattern was found in left amygdala. There were no effects of COMT genotype on volumes of the whole brain or the other selected regions. Our findings support recent reports of neuroanatomical changes associated with cannabis use and, for the first time, reveal that these changes may be influenced by the COMT genotype.
Collapse
Affiliation(s)
- Albert Batalla
- Department of Psychiatry; Clinical Institute of Neuroscience; Hospital Clínic, IDIBAPS, CIBERSAM; Spain
- Department of Psychiatry and Clinical Psychobiology; University of Barcelona; Spain
| | - Carles Soriano-Mas
- CRC Mar; Hospital del Mar; Spain
- Department of Psychiatry; Bellvitge University Hospital-IDIBELL, CIBERSAM; Spain
| | | | - Marta Torrens
- Neuroscience Program; IMIM (Hospital del Mar Medical Research Institute)-INAD-Parc de Salut Mar, Autonomous University of Barcelona and Pompeu Fabra University; Spain
- Red de Trastornos Adictivos (RETIC); IMIM-INAD-Parc de Salut Mar; Spain
| | - José A. Crippa
- Neuroscience and Cognitive Behavior Department; University of Sao Paulo; Brazil
- INCT Translational Medicine (INCT-TM, CNPq); Brazil
| | - Sagnik Bhattacharyya
- Department of Psychosis Studies; King's College London, Institute of Psychiatry; UK
| | | | - Ana B. Fagundo
- Neuroscience Program; IMIM (Hospital del Mar Medical Research Institute)-INAD-Parc de Salut Mar, Autonomous University of Barcelona and Pompeu Fabra University; Spain
| | - Ben J. Harrison
- CRC Mar; Hospital del Mar; Spain
- Melbourne Neuropsychiatry Centre; Department of Psychiatry; The University of Melbourne & Melbourne Health; Australia
| | - Santiago Nogué
- Clinical Toxicology Unit; Emergency Department; Hospital Clínic, IDIBAPS, University of Barcelona; Spain
| | - Rafael de la Torre
- Neuroscience Program; IMIM (Hospital del Mar Medical Research Institute)-INAD-Parc de Salut Mar, Autonomous University of Barcelona and Pompeu Fabra University; Spain
- CIBEROBN; Spain
| | - Magí Farré
- Neuroscience Program; IMIM (Hospital del Mar Medical Research Institute)-INAD-Parc de Salut Mar, Autonomous University of Barcelona and Pompeu Fabra University; Spain
- Red de Trastornos Adictivos (RETIC); IMIM-INAD-Parc de Salut Mar; Spain
| | | | - Rocío Martín-Santos
- Department of Psychiatry; Clinical Institute of Neuroscience; Hospital Clínic, IDIBAPS, CIBERSAM; Spain
- Department of Psychiatry and Clinical Psychobiology; University of Barcelona; Spain
- Neuroscience Program; IMIM (Hospital del Mar Medical Research Institute)-INAD-Parc de Salut Mar, Autonomous University of Barcelona and Pompeu Fabra University; Spain
- Neuroscience and Cognitive Behavior Department; University of Sao Paulo; Brazil
| |
Collapse
|
21
|
Batalla A, Crippa J, Busatto G, Guimaraes F, Zuardi A, Valverde O, Atakan Z, McGuire P, Bhattacharyya S, Martín-Santos R. Neuroimaging Studies of Acute Effects of THC and CBD in Humans and Animals: a Systematic Review. Curr Pharm Des 2014; 20:2168-85. [DOI: 10.2174/13816128113199990432] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2013] [Accepted: 06/10/2013] [Indexed: 11/22/2022]
|
22
|
Grande I, Magalhães PVS, Chendo I, Stertz L, Fries GR, Cereser KM, Cunha ÂBM, Gói P, Kunz M, Udina M, Martín-Santos R, Frey BN, Vieta E, Kapczinski F. Val66Met polymorphism and serum brain-derived neurotrophic factor in bipolar disorder: an open-label trial. Acta Psychiatr Scand 2014; 129:393-400. [PMID: 23957567 DOI: 10.1111/acps.12192] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 07/11/2013] [Indexed: 12/21/2022]
Abstract
OBJECTIVE Brain-derived neurotrophic factor (BDNF) is consistently associated with acute mood episodes in bipolar disorder, but there is a lack of longitudinal data to support this hypothesis. In this 16-week open-label clinical trial, we tested the predictive role of BDNF Val66Met polymorphism on serum BDNF levels and the relationship of serum BDNF and clinical response in people with bipolar disorder during an acute illness episode. METHOD Sixty-four people with bipolar disorder who were medication-free at baseline and in an acute mood episode were recruited. They were matched with 64 healthy controls. Clinical evaluation, serum BDNF, and BDNF Val66Met polymorphism were determined at baseline, and change in serum BDNF was assessed in patients at weeks 2, 4, 8 and 16. RESULTS There were no differences between patients and controls in serum BDNF or in frequencies of the BDNF Val66Met polymorphism genotype at baseline. The multivariable model showed that Met carriers had a significantly different change in BDNF levels compared with Val homozygotes. Not achieving a complete remission was also associated with lower prospectively assessed BDNF levels. CONCLUSION This study provides the first longitudinal evidence that both the BDNF Val66Met polymorphism and remission status predict change in circulating BDNF levels.
Collapse
Affiliation(s)
- I Grande
- Bipolar Disorders Unit, IDIBAPS, CIBERSAM, Clinical Institute of Neurosciences, Hospital Clínic, University of Barcelona, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Pujol J, Blanco-Hinojo L, Batalla A, López-Solà M, Harrison BJ, Soriano-Mas C, Crippa JA, Fagundo AB, Deus J, de la Torre R, Nogué S, Farré M, Torrens M, Martín-Santos R. Functional connectivity alterations in brain networks relevant to self-awareness in chronic cannabis users. J Psychiatr Res 2014; 51:68-78. [PMID: 24411594 DOI: 10.1016/j.jpsychires.2013.12.008] [Citation(s) in RCA: 71] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/16/2013] [Revised: 11/15/2013] [Accepted: 12/17/2013] [Indexed: 01/12/2023]
Abstract
BACKGROUND Recreational drugs are generally used to intentionally alter conscious experience. Long-lasting cannabis users frequently seek this effect as a means to relieve negative affect states. As with conventional anxiolytic drugs, however, changes in subjective feelings may be associated with memory impairment. We have tested whether the use of cannabis, as a psychoactive compound, is associated with alterations in spontaneous activity in brain networks relevant to self-awareness, and whether such potential changes are related to perceived anxiety and memory performance. METHODS Functional connectivity was assessed in the Default and Insula networks during resting state using fMRI in 28 heavy cannabis users and 29 control subjects. Imaging assessments were conducted during cannabis use in the unintoxicated state and repeated after one month of controlled abstinence. RESULTS Cannabis users showed increased functional connectivity in the core of the Default and Insula networks and selective enhancement of functional anticorrelation between both. Reduced functional connectivity was observed in areas overlapping with other brain networks. Observed alterations were associated with behavioral measurements in a direction suggesting anxiety score reduction and interference with memory performance. Alterations were also related to the amount of cannabis used and partially persisted after one month of abstinence. CONCLUSIONS Chronic cannabis use was associated with significant effects on the tuning and coupling of brain networks relevant to self-awareness, which in turn are integrated into brain systems supporting the storage of personal experience and motivated behavior. The results suggest potential mechanisms for recreational drugs to interfere with higher-order network interactions generating conscious experience.
Collapse
Affiliation(s)
- Jesus Pujol
- MRI Research Unit, CRC Mar, Hospital del Mar, Barcelona, Spain.
| | - Laura Blanco-Hinojo
- MRI Research Unit, CRC Mar, Hospital del Mar, Barcelona, Spain; Human Pharmacology and Neurosciences, Institute of Neuropsychiatry and Addiction, Hospital del Mar Research Institute, Barcelona, Spain
| | - Albert Batalla
- Clinical Institute of Neuroscience, Hospital Clínic, IDIBAPS, CIBERSAM, University of Barcelona, Barcelona, Spain; Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Barcelona, Spain
| | - Marina López-Solà
- MRI Research Unit, CRC Mar, Hospital del Mar, Barcelona, Spain; Department of Psychology and Neuroscience, University of Colorado, Boulder, CO, USA
| | - Ben J Harrison
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne, Melbourne, Australia
| | - Carles Soriano-Mas
- Department of Psychiatry, Bellvitge University Hospital-IDIBELL, Barcelona, Spain; Carlos III Health Institute, Ministry of Science and Innovation, CIBERSAM, Spain
| | - Jose A Crippa
- Department of Neuroscience and Behavior, RibeirãoPreto Medical School, University of São Paulo, Brazil; INCT Translational Medicine (CNPq), Brazil
| | - Ana B Fagundo
- Human Pharmacology and Neurosciences, Institute of Neuropsychiatry and Addiction, Hospital del Mar Research Institute, Barcelona, Spain
| | - Joan Deus
- MRI Research Unit, CRC Mar, Hospital del Mar, Barcelona, Spain; Department of Clinical and Health Psychology, Autonomous University of Barcelona, Spain
| | - Rafael de la Torre
- Human Pharmacology and Neurosciences, Institute of Neuropsychiatry and Addiction, Hospital del Mar Research Institute, Barcelona, Spain; Red-Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, Spain
| | - Santiago Nogué
- Section of Clinical Toxicology, Emergency Service, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
| | - Magí Farré
- Human Pharmacology and Neurosciences, Institute of Neuropsychiatry and Addiction, Hospital del Mar Research Institute, Barcelona, Spain; School of Medicine, Autonomous University of Barcelona, Red de Trastornos Adictivos (RETIC), Barcelona, Spain
| | - Marta Torrens
- Human Pharmacology and Neurosciences, Institute of Neuropsychiatry and Addiction, Hospital del Mar Research Institute, Barcelona, Spain; School of Medicine, Autonomous University of Barcelona, Red de Trastornos Adictivos (RETIC), Barcelona, Spain
| | - Rocío Martín-Santos
- Clinical Institute of Neuroscience, Hospital Clínic, IDIBAPS, CIBERSAM, University of Barcelona, Barcelona, Spain; Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Barcelona, Spain; INCT Translational Medicine (CNPq), Brazil
| |
Collapse
|
24
|
Fonseca F, Gratacòs M, Escaramís G, De Cid R, Martín-Santos R, Farré M, Estivill X, Torrens M. ALDH5A1 variability in opioid dependent patients could influence response to methadone treatment. Eur Neuropsychopharmacol 2014; 24:420-4. [PMID: 24230997 DOI: 10.1016/j.euroneuro.2013.10.003] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/04/2013] [Revised: 09/04/2013] [Accepted: 10/09/2013] [Indexed: 11/17/2022]
Abstract
Methadone maintenance treatment is the most widely-used therapy in opioid dependence, but some patients relapse or drop out from treatment. We genotyped a genetic variant in the succinic semialdehyde dehydrogenase enzyme gene, ALDH5A1, and found that subjects carrying the T variant allele have a higher risk to be nonresponders to methadone treatment (OR=3.16; 95% CI [1.48-6.73], P=0.0024). This could be due to a reduction in the ALDH5A1 enzyme activity, that would increase endogenous gamma-hydroxbutyric acid (GHB) and gamma-aminobutyric acid (GABA) levels and therefore, inducing symptoms such as sedation and impaired pschomotor performance. These neuropsychological effects related with the reduction in enzyme activity could be responsible for a higher propensity to relapse in these genetically predisposed patients.
Collapse
Affiliation(s)
- Francina Fonseca
- Institut de Neuropsiquiatria i Addicions, Hospital del Mar, Barcelona, Spain; Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain
| | - Mònica Gratacòs
- CIBER Epidemiología y Salud Pública (CIBERESP) and Genes and Disease Program, Barcelona, Spain
| | - Geòrgia Escaramís
- CIBER Epidemiología y Salud Pública (CIBERESP) and Genes and Disease Program, Barcelona, Spain
| | - Rafael De Cid
- CIBER Epidemiología y Salud Pública (CIBERESP) and Genes and Disease Program, Barcelona, Spain; Center for Genomic Regulation (CRG-UPF), Parc de Recerca Biomèdica (PRBB), Barcelona, Spain
| | - Rocío Martín-Santos
- Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain; Service of Psychiatry and Psychology, Neuroscience Institute, Hospital Clinic, Institut d'Investigació Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Barcelona, Spain; Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Barcelona, Spain
| | - Magi Farré
- Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain; Psychiatry and Pharmacology Departments, Autonomous University of Barcelona, Barcelona, Spain
| | - Xavier Estivill
- CIBER Epidemiología y Salud Pública (CIBERESP) and Genes and Disease Program, Barcelona, Spain; Center for Genomic Regulation (CRG-UPF), Parc de Recerca Biomèdica (PRBB), Barcelona, Spain; Experimental and Health Sciences Department, Pompeu Fabra University, Barcelona, Spain
| | - Marta Torrens
- Institut de Neuropsiquiatria i Addicions, Hospital del Mar, Barcelona, Spain; Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain; Psychiatry and Pharmacology Departments, Autonomous University of Barcelona, Barcelona, Spain.
| |
Collapse
|
25
|
Mestre-Pintó JI, Domingo-Salvany A, Martín-Santos R, Torrens M. Dual diagnosis screening interview to identify psychiatric comorbidity in substance users: development and validation of a brief instrument. Eur Addict Res 2014; 20:41-8. [PMID: 23921461 DOI: 10.1159/000351519] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/16/2012] [Accepted: 04/15/2013] [Indexed: 11/19/2022]
Abstract
AIM The objective of this study was to develop and validate a brief tool, the Dual Diagnosis Screening Instrument (DDSI), to screen psychiatric disorders in substance users in treatment and nontreatment-seeking samples. METHODS A total of 827 substance users (66.5% male, mean age 28.6±9.9 years) recruited in treatment (in- and outpatient) and nontreatment (substance user volunteers in university research studies) settings were assessed by trained interviewers using the DDSI and the Psychiatric Research Interview for Substance and Mental Disorders (PRISM) as the criterion standard. Both instruments were administered blind to the results of the other. Disorders obtained with the DDSI were compared to lifetime diagnoses obtained with the PRISM. Sensitivity, specificity, negative, and positive predictive values were estimated. Also test-retest reliability of the DDSI was assessed. RESULTS The DDSI showed a high sensitivity (≥80%) for identifying lifetime depression, mania, psychosis, panic, social phobia, and specific phobia disorders. Specificity was ≥82% for those diagnoses. Test-retest κ showed excellent agreement (range 81-95%). The mean duration of the DDSI administration was 16.8±2.5 min. CONCLUSION The DDSI is a valid and easy-to-administer screening tool to detect possible psychiatric comorbidity among substance users.
Collapse
|
26
|
Fabrega Ribera M, Ilzarbe D, Mansilla S, Pérez A, Vázquez M, Soler V, Martín-Santos R, Lázaro L. EPA-1231 – Study of psychiatric emergencies in children and adolescents. Eur Psychiatry 2014. [DOI: 10.1016/s0924-9338(14)78473-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
27
|
Batalla A, Fagundo A, Blanco-Hinojo L, Soriano-Mas C, Navinés R, Farré M, Udina M, De la Torre R, Bhattacharyya S, Crippa J, Pujol J, Torrens M, Martín-Santos R. EPA-1084 - Catechol o-methyltransferase val158met genotype and neural mechanisms related to response inhibition in chronic cannabis users. Eur Psychiatry 2014. [DOI: 10.1016/s0924-9338(14)78362-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
28
|
Udina M, Navinés R, Capuron L, Martín-Santos R. A response to the commentary "Indolamine 2,3-dioxygenase regulation and neuropsychiatric symptoms" by Loftis, J.M. on "Serotonin and interleukin-6: the role of genetic polymorphisms in IFN-induced neuropsychiatric symptoms" by Udina, M., Moreno-España, J., Navinés, R., Gimenez, D., Langohr, K., Gratacòs, M., Capuron, L., de la Torre, R., Solà, R., Martin-Santos, R. http:\\dx.doi.org/10.1016/j.psyneuen.2013.03.007. Psychoneuroendocrinology 2013; 38:1830-1. [PMID: 23810434 DOI: 10.1016/j.psyneuen.2013.05.019] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/29/2013] [Accepted: 05/30/2013] [Indexed: 12/26/2022]
Affiliation(s)
- Marc Udina
- Department of Psychiatry and Psychology, Hospital Clínic, IDIBAPS, CIBERSAM, Spain; Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Catalonia, Spain
| | | | | | | |
Collapse
|
29
|
Atakan Z, Bhattacharyya S, Allen P, Martín-Santos R, Crippa JA, Borgwardt SJ, Fusar-Poli P, Seal M, Sallis H, Stahl D, Zuardi AW, Rubia K, McGuire P. Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers. Psychol Med 2013; 43:1255-1267. [PMID: 23020923 DOI: 10.1017/s0033291712001924] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND Cannabis can induce transient psychotic symptoms, but not all users experience these adverse effects. We compared the neural response to Δ9-tetrahydrocannabinol (THC) in healthy volunteers in whom the drug did or did not induce acute psychotic symptoms. Method In a double-blind, placebo-controlled, pseudorandomized design, 21 healthy men with minimal experience of cannabis were given either 10 mg THC or placebo, orally. Behavioural and functional magnetic resonance imaging measures were then recorded whilst they performed a go/no-go task. RESULTS The sample was subdivided on the basis of the Positive and Negative Syndrome Scale positive score following administration of THC into transiently psychotic (TP; n = 11) and non-psychotic (NP; n = 10) groups. During the THC condition, TP subjects made more frequent inhibition errors than the NP group and showed differential activation relative to the NP group in the left parahippocampal gyrus, the left and right middle temporal gyri and in the right cerebellum. In these regions, THC had opposite effects on activation relative to placebo in the two groups. The TP group also showed less activation than the NP group in the right middle temporal gyrus and cerebellum, independent of the effects of THC. CONCLUSIONS In this first demonstration of inter-subject variability in sensitivity to the psychotogenic effects of THC, we found that the presence of acute psychotic symptoms was associated with a differential effect of THC on activation in the ventral and medial temporal cortex and cerebellum, suggesting that these regions mediate the effects of the drug on psychotic symptoms.
Collapse
Affiliation(s)
- Z Atakan
- Section of Neuroimaging, Department of Psychosis Studies, Institute of Psychiatry, King's College London, London, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Pujol J, Giménez M, Ortiz H, Soriano-Mas C, López-Solà M, Farré M, Deus J, Merlo-Pich E, Harrison BJ, Cardoner N, Navinés R, Martín-Santos R. Neural response to the observable self in social anxiety disorder. Psychol Med 2013; 43:721-731. [PMID: 22895096 DOI: 10.1017/s0033291712001857] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND Distorted images of the observable self are considered crucial in the development and maintenance of social anxiety. We generated an experimental situation in which participants viewed themselves from an observer's perspective when exposed to scrutiny and evaluation by others. Method Twenty patients with social anxiety disorder (SAD) and 20 control subjects were assessed using functional magnetic resonance imaging (fMRI) during the public exposure of pre-recorded videos in which they were each shown performing a verbal task. The examiners acted as the audience in the experiment and rated performance. Whole-brain functional maps were computed using Statistical Parametric Mapping. RESULTS Robust activation was observed in regions related to self-face recognition, emotional response and general arousal in both study groups. Patients showed significantly greater activation only in the primary visual cortex. By contrast, they showed significant deactivation or smaller activation in dorsal frontoparietal and anterior cingulate cortices relevant to the cognitive control of negative emotion. Task-related anxiety ratings revealed a pattern of negative correlation with activation in this frontoparietal/cingulate network. Importantly, the relationship between social anxiety scores and neural response showed an inverted-U function with positive correlations in the lower score range and negative correlations in the higher range. CONCLUSIONS Our findings suggest that exposure to scrutiny and evaluation in SAD may be associated with changes in cortical systems mediating the cognitive components of anxiety. Disorder severity seems to be relevant in shaping the neural response pattern, which is distinctively characterized by a reduced cortical response in the most severe cases.
Collapse
Affiliation(s)
- J Pujol
- Institut d'Alta Tecnologia-PRBB, CRC Mar, Hospital de Mar, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Sanches SHB, Osório FDL, Udina M, Martín-Santos R, Crippa JAS. Anxiety and joint hypermobility association: a systematic review. Braz J Psychiatry 2013; 34 Suppl 1:S53-60. [PMID: 22729449 DOI: 10.1590/s1516-44462012000500005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
BACKGROUND Anxiety disorders are often associated with several non-psychiatric medical conditions. Among the clinical conditions found in association with anxiety stands out the joint hypermobility (JH). OBJECTIVES To carry out a systematic review of the clinical association between anxiety disorders and JH. METHOD A survey was conducted in MEDLINE, PsychINFO, LILACS e SciELO databases up to December 2011. We searched for articles using the keywords 'anxiety', 'joint' and 'hypermobility' and Boolean operators. The review included articles describing empirical studies on the association between JH and anxiety. The reference lists of selected articles were systematically hand-searched for other publications relevant to the review. RESULTS Seventeen articles were included in the analysis and classified to better extract data. We found heterogeneity between the studies relate to the methodology used. Most of the studies found an association between anxiety features and JH. Panic disorder/agoraphobia was the anxiety disorder associated with JH in several studies. Etiological explanation of the relationship between anxiety and JH is still controversial. CONCLUSION Future research in large samples from the community and clinical setting and longitudinal studies of the association between anxiety and HA and the underlying biological mechanisms involved in this association are welcome.
Collapse
Affiliation(s)
- Simone H Bianchi Sanches
- Neurosciences and Behavior Department, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Brazil.
| | | | | | | | | |
Collapse
|
32
|
Binelli C, Ortiz A, Muñiz A, Gelabert E, Ferraz L, S Filho A, Crippa JAS, Nardi AE, Subirà S, Martín-Santos R. Social anxiety and negative early life events in university students. Braz J Psychiatry 2013; 34 Suppl 1:S69-74. [PMID: 22729450 DOI: 10.1590/s1516-44462012000500006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
INTRODUCTION There is substantial evidence regarding the impact of negative life events during childhood on the aetiology of psychiatric disorders. We examined the association between negative early life events and social anxiety in a sample of 571 Spanish University students. METHODS In a cross-sectional survey conducted in 2007, we collected data through a semistructured questionnaire of sociodemographic variables, personal and family psychiatric history, and substance abuse. We assessed the five early negative life events: (i) the loss of someone close, (ii) emotional abuse, (iii) physical abuse, (iv) family violence, and (v) sexual abuse. All participants completed the Liebowitz Social Anxiety Scale. RESULTS Mean (SD) age was 21 (4.5), 75% female, LSAS score was 40 (DP = 22), 14.2% had a psychiatric family history and 50.6% had negative life events during childhood. Linear regression analyses, after controlling for age, gender, and family psychiatric history, showed a positive association between family violence and social score (p = 0.03). None of the remaining stressors produced a significant increase in LSAS score (p > 0.05). CONCLUSION University students with high levels of social anxiety presented higher prevalence of negative early life events. Thus, childhood family violence could be a risk factor for social anxiety in such a population.
Collapse
Affiliation(s)
- Cynthia Binelli
- Department of Psychiatry, Hospital Parc Taulí, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Udina M, Foulon H, Valdés M, Bhattacharyya S, Martín-Santos R. Dhat syndrome: a systematic review. Psychosomatics 2013; 54:212-8. [PMID: 23352282 DOI: 10.1016/j.psym.2012.09.003] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/02/2012] [Revised: 09/17/2012] [Accepted: 09/17/2012] [Indexed: 01/21/2023]
Abstract
BACKGROUND Dhat syndrome is a widely recognized clinical condition often seen on the Indian subcontinent that is characterized by a preoccupation with semen loss in urine and other symptoms such as fatigue or depressed mood. Although it has been considered to be a culture-bound syndrome, it may also be regarded as a distinct manifestation of depression or another medical illness. OBJECTIVE The purpose of this paper was to carry out a systematic review on Dhat syndrome. METHODS A review of the literature published up until February 2012 was conducted using the key words [Dhat syndrome] or [semen-loss anxiety] or [semen-loss syndrome]. We included only original studies. REVIEW The majority of studies reported patients from the Indian subcontinent. There was a high degree of heterogeneity among the studies. Dhat was a common condition in young people from certain cultures and origins. Depressive and anxiety symptoms were common, including fatigue, sleepiness, and sexual dysfunction. Good clinical engagement, social support, and sexual education were useful in some cases. Given the high rate of comorbid depressive symptoms, antidepressant has been used. DISCUSSION In an increasingly globalized world, clinicians must be able to properly diagnose and treat patients from other cultures, who may report symptoms that are influenced by their beliefs, culture, or place of origin. Dhat may be a common manifestation of a depressive or anxiety disorder in certain cultures. Further research is needed to improve our understanding of this condition, to clarify its nosologic status, and to offer appropriate treatment to affected individuals.
Collapse
Affiliation(s)
- Marc Udina
- Clinical Neuroscience Institute, Hospital Clinic, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
| | | | | | | | | |
Collapse
|
34
|
Udina M, Moreno-España J, Navinés R, Langohr K, Gratacós M, Forns X, Capuron L, Vieta E, Solà R, Martín-Santos R. 1646 – Genetic risk factors for interferon-induced anxiety. Eur Psychiatry 2013. [DOI: 10.1016/s0924-9338(13)76636-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
35
|
Batalla A, Bhattachayyria S, Yucel M, Fusar-Poli P, Crippa J, Nogué S, Torrens M, Pujol J, Farré M, Martín-Santos R. 1301 – Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. Eur Psychiatry 2013. [DOI: 10.1016/s0924-9338(13)76359-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
36
|
Navinés R, Gutiérrez F, Subirà S, Obiols J, Binelly C, Martín-Santos R. 1872 – Comorbidity between panic disorder with and without co-occurring depression and personality disorders: a systematic review. Eur Psychiatry 2013. [DOI: 10.1016/s0924-9338(13)76831-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
37
|
Plaza A, Garcia-Esteve L, Torres A, Ascaso C, Gelabert E, Luisa Imaz M, Navarro P, Valdés M, Martín-Santos R. Childhood physical abuse as a common risk factor for depression and thyroid dysfunction in the earlier postpartum. Psychiatry Res 2012; 200:329-35. [PMID: 22878032 DOI: 10.1016/j.psychres.2012.06.032] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/12/2012] [Revised: 06/17/2012] [Accepted: 06/21/2012] [Indexed: 01/05/2023]
Abstract
Childhood abuse is a powerful risk factor for developing postpartum depression in adulthood, and recently it has been associated to thyroid dysfunction in postpartum depressive women. The purpose of this study was to investigated the effects of childhood abuse on thyroid status and depressive symptomatology in two hundred and thirty-six (n=236) postpartum women 24-48h after delivery. The Early-Trauma-Inventory Self-Report was used to assess the presence of childhood abuse and the Edinburgh Postpartum Depression Scale (EPDS) to evaluate depressive symptomatology (EPDS≥11). Free thyroxin (fT4) and thyroid-stimulating hormone (TSH) were measured. Thyroid dysfunction (TD) was defined as altered TSH or TSH and fT4. Socio-demographic, reproductive, and psychopathological variables were also collected. Multivariate analysis shows that childhood physical abuse increases by four times the risk for TD (OR: 3.95, 95% CI: 1.23-12.71) and five times the risk for depressive symptomatology (OR: 5.45, 95% CI: 2.17-13.66) in the earlier postpartum. Our findings suggest that women with history of childhood physical abuse are particularly at-risk for thyroid dysfunction and depressive symptomatology 24-48h after delivery. The assessment of childhood abuse in the perinatal period is important to identify women at-risk for physical and mental health problems in this period.
Collapse
Affiliation(s)
- Anna Plaza
- Unit of Perinatal Psychiatry and Gender Research, Hospital Clinic Universitari of Barcelona, IDIBAPS, Barcelona 08028, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Udina M, Castellví P, Moreno-España J, Navinés R, Valdés M, Forns X, Langohr K, Solà R, Vieta E, Martín-Santos R. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry 2012; 73:1128-38. [PMID: 22967776 DOI: 10.4088/jcp.12r07694] [Citation(s) in RCA: 211] [Impact Index Per Article: 17.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2012] [Accepted: 03/28/2012] [Indexed: 10/28/2022]
Abstract
OBJECTIVE To carry out a systematic review of the risk factors for, and incidence of, major depressive episode (MDE) related to antiviral therapy for chronic hepatitis C. DATA SOURCES The MEDLINE, PsycINFO, and Cochrane databases were searched to locate articles published from the earliest available online year until June 2011 using the keywords hepatitis C, interferon-alpha, peginterferon, pegylated interferon, depression, and mood and Boolean operators. Articles written in English, Spanish, and French were included. STUDY SELECTION Prospective studies reporting incidence of interferon-alpha-induced MDE were included. At baseline, patients did not present a DSM-IV/ICD depressive episode, and evaluation was performed by a trained clinician. Twenty-six observational studies met the inclusion criteria. DATA EXTRACTION Extracted data included authors, year of publication, design, characteristics of the population, viral coinfection, adjunctive psychopharmacology, instruments to assess depression, dose and type of interferon-alpha, adjunctive ribavirin treatment, and follow-up time. Outcome of incidence of MDE (primary outcome measure) was abstracted, as were potential predictive variables. DATA SYNTHESIS A full review was performed. Meta-analysis of the cumulative incidence of induced MDE as a function of time was carried out. Odds ratios (ORs) and mean differences were used to estimate the strength of association of variables. RESULTS Overall cumulative incidence of depression was 0.25 (95% CI, 0.16 to 0.35) and 0.28 (95% CI, 0.17 to 0.42) at 24 and 48 weeks of treatment, respectively. According to our analysis, high baseline levels of interleukin 6 (mean difference = 1.81; 95% CI, 1.09 to 2.52), female gender (OR = 1.40; 95% CI, 1.02 to 1.91), history of MDE (OR = 3.96; 95% CI, 2.52 to 6.21), history of psychiatric disorder (OR = 3.18; 95% CI, 1.60 to 6.32), subthreshold depressive symptoms (mean difference = 0.96; 95% CI, 0.31 to 1.61), and low educational level (mean difference = -0.99; 95% CI, -1.59 to -0.39) were predictive variables of MDE during antiviral treatment. CONCLUSIONS One in 4 chronic hepatitis C patients who start interferon and ribavirin treatment will develop an induced major depressive episode. Clinicians should attempt a full evaluation of patients before starting antiviral treatment in order to identify those at risk of developing interferon-induced depression.
Collapse
Affiliation(s)
- Marc Udina
- Clinical Institute of Neuroscience, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Binelli C, Ortiz A, Muñiz A, Gelabert E, Ferraz L, Filho AS, Crippa JAS, Nardi AE, Subirà S, Martín-Santos R. Social anxiety and negative early life events in university students. Revista Brasileira de Psiquiatria 2012. [DOI: 10.1016/s1516-4446(12)70055-7] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
40
|
Bianchi Sanches SH, Osório FDL, Udina M, Martín-Santos R, Crippa JAS. Anxiety and joint hypermobility association: a systematic review. Revista Brasileira de Psiquiatria 2012. [DOI: 10.1016/s1516-4446(12)70054-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
41
|
Navinés R, Blanch J, Rousaud A, Moreno-España J, Martín-Santos R. A non-affective psychotic syndrome after starting antiretroviral therapy. Braz J Psychiatry 2012; 34:226-227. [PMID: 22729423 DOI: 10.1590/s1516-44462012000200019] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Affiliation(s)
- R Navinés
- Clinical Institute of Neurosciences, Hospital Clinic
| | | | | | | | | |
Collapse
|
42
|
Gelabert E, Subirà S, García-Esteve L, Navarro P, Plaza A, Cuyàs E, Navinés R, Gratacòs M, Valdés M, Martín-Santos R. Perfectionism dimensions in major postpartum depression. J Affect Disord 2012; 136:17-25. [PMID: 21930303 DOI: 10.1016/j.jad.2011.08.030] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2010] [Revised: 08/12/2011] [Accepted: 08/24/2011] [Indexed: 10/17/2022]
Abstract
BACKGROUND Although perfectionism from a multidimensional perspective has generally been associated with depressive illness, there are not many studies on its role in major depression in the postnatal period. The aim of the present study was to explore the relationship between perfectionism dimensions using the Frost Multidimensional Perfectionism Scale (FMPS) and major postpartum depression. METHODS One-hundred-twenty-two women with major postpartum depression (SCID-I; DSM-IV) and 115 healthy postpartum women were evaluated using the FMPS, an instrument for the assessment of six perfectionism dimensions: concern over mistakes, personal standards, parental expectations, parental criticism, doubt about actions and organisation. Other variables were also considered: neuroticism, psychiatric history, social support, life events and genotype combinations according to serotonin transporter expression (5-HTTLPR and Stin2 VNTR polymorphisms). RESULTS The prevalence of high-perfectionism was higher in major postpartum depression group than in control group (34% vs. 11%; p<0.001). Multivariate models confirmed high-perfectionism as an independent factor associated with major postpartum depression. Specifically, the high-concern over mistakes dimension increased over four-fold the odds of major depression in postpartum period. (OR=4.14; 95% CI=1.24-13.81) Neuroticism, personal psychiatric history and 5-HTT low-expressing genotypes at one of the loci were also identified as independent factors. CONCLUSIONS High-perfectionism, and particularly high-concern over mistakes is a personality dimension associated with major postpartum depression. The inclusion of perfectionism assessment, together with others factors, may be considered in order to improve the detection of women at risk of postpartum depression, in whom early intervention may be of benefit.
Collapse
Affiliation(s)
- Estel Gelabert
- Department of Clinical and Health Psychology, Universitat Autònoma de Barcelona, Bellaterra, Spain; Neuropsychopharmacology Programe, IMIM-Parc de Salut Mar, Barcelona, Spain
| | - Susana Subirà
- Department of Clinical and Health Psychology, Universitat Autònoma de Barcelona, Bellaterra, Spain
| | - Lluisa García-Esteve
- Neuroscience Institute, Hospital Clínic, Universitat de Barcelona (UB), IDIBAPS, Barcelona, Spain
| | - Purificación Navarro
- Neuroscience Institute, Hospital Clínic, Universitat de Barcelona (UB), IDIBAPS, Barcelona, Spain
| | - Anna Plaza
- Neuroscience Institute, Hospital Clínic, Universitat de Barcelona (UB), IDIBAPS, Barcelona, Spain
| | - Elisabet Cuyàs
- Neuropsychopharmacology Programe, IMIM-Parc de Salut Mar, Barcelona, Spain; Universitat Autònoma de Barcelona, Spain
| | - Ricard Navinés
- Neuropsychopharmacology Programe, IMIM-Parc de Salut Mar, Barcelona, Spain; Neuroscience Institute, Hospital Clínic, Universitat de Barcelona (UB), IDIBAPS, Barcelona, Spain; CIBERSAM, Barcelona, Spain
| | - Mònica Gratacòs
- Genes and Disease Program, Center for Genomic Regulation (CRG-UPF), CIBER en Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
| | - Manuel Valdés
- Neuroscience Institute, Hospital Clínic, Universitat de Barcelona (UB), IDIBAPS, Barcelona, Spain
| | - Rocío Martín-Santos
- Neuropsychopharmacology Programe, IMIM-Parc de Salut Mar, Barcelona, Spain; Neuroscience Institute, Hospital Clínic, Universitat de Barcelona (UB), IDIBAPS, Barcelona, Spain; CIBERSAM, Barcelona, Spain.
| |
Collapse
|
43
|
Filho AS, Maciel BC, Romano MMD, Lascala TF, Trzesniak C, Freitas-Ferrari MC, Nardi AE, Martín-Santos R, Zuardi AW, Crippa JAS. Mitral valve prolapse and anxiety disorders. Br J Psychiatry 2011; 199:247-8. [PMID: 21881100 DOI: 10.1192/bjp.bp.111.091934] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
We investigated whether there is an association between anxiety disorders and mitral valve prolapse. We compared mitral valve prolapse prevalence in individuals with panic disorder (n = 41), social anxiety disorder (n = 89) and in healthy controls (n = 102) in an attempt to overcome the biases of previous studies. Our results show no associations between panic disorder or social anxiety disorder and mitral valve prolapse, regardless of the diagnostic criteria employed, and that the relationship between these conditions seems not to be clinically relevant.
Collapse
Affiliation(s)
- Alaor S Filho
- Hospital das Clínicas - Terceiro Andar; Av. Bandeirantes, 3900; RibeirãoPreto -São Paulo, CEP - 14049-900, Brazil
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Filho AS, Maciel BC, Martín-Santos R, Romano MMD, Crippa JA. Does the association between mitral valve prolapse and panic disorder really exist? Prim Care Companion J Clin Psychiatry 2011; 10:38-47. [PMID: 18311420 DOI: 10.4088/pcc.v10n0107] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/15/2007] [Accepted: 06/13/2007] [Indexed: 10/20/2022]
Abstract
OBJECTIVE Although the possible relationship between panic disorder and mitral valve prolapse (MVP) attracted considerable research interest in the 1980s and 1990s, the reported prevalence of MVP in these patients has been inconsistent and widely variable. Clinical and epidemiologic studies have produced controversial data on possible association or definite causal relationship between these 2 entities. The primary objective of the present review was to summarize the current state of knowledge on the association between panic disorder and MVP, including the influence of diagnostic criteria for MVP on the controversial results. DATA SOURCES We searched MEDLINE, LILACS, and EMBASE databases using the keywords panic and mitral. Inclusion criteria were articles concerning the reciprocal association of MVP and panic disorder, published from the earliest dates available through December 2006. STUDY SELECTION All relevant articles published in English, Spanish, or Portuguese and reporting original data related to the association of MVP and panic disorder were included. Forty articles fulfilling the criteria for inclusion in this review were identified. DATA SYNTHESIS Even though the reported prevalence of MVP in panic disorder varied from 0% to 57%, a significant association between the 2 disorders was documented in 17 of the 40 studies. Such inconsistent results were due to sampling biases in case or control groups, widely different diagnostic criteria for MVP, and lack of reliability of MVP diagnosis. None of the reviewed studies used the current state-of-the-art diagnostic criteria for MVP to evaluate the volunteers. Apparently, the more elaborate the study methodology, the lower the chance to observe a significant relationship between these 2 conditions. CONCLUSIONS Published results are insufficient to definitely establish or to exclude an association between MVP and panic disorder. If any relationship does actually exist, it could be said to be infrequent and mainly occur in subjects with minor variants of MVP. To clarify this intriguing issue, future studies should mainly focus on the observed methodological biases and particularly should use the current criteria for MVP as the standard for evaluation.
Collapse
Affiliation(s)
- Alaor Santos Filho
- Department of Neuropsychiatry and Medical Psychology, School of Medicine of Ribeirão Preto, São Paulo University, Brazil
| | | | | | | | | |
Collapse
|
45
|
Mendoza L, Navinés R, Crippa JA, Fagundo AB, Gutierrez F, Nardi AE, Bulbena A, Valdés M, Martín-Santos R. Depersonalization and personality in panic disorder. Compr Psychiatry 2011; 52:413-9. [PMID: 21683177 DOI: 10.1016/j.comppsych.2010.09.002] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/05/2010] [Revised: 09/10/2010] [Accepted: 09/17/2010] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND Prevalence and clinical correlates of depersonalization symptoms have been associated with panic disorder. Personality traits might increase the likelihood of experiencing depersonalization symptoms or depersonalization disorder in panic patients. AIMS The objectives of this study are to establish the prevalence of depersonalization symptoms during the panic attack and in depersonalization disorder and to examine the personality factors associated with the presence of depersonalization in patients with panic disorder. METHODS The sample comprised 104 consecutive adult outpatients with panic disorder, diagnosed according to the Semistructured Clinical Interview for DSM-IV (Axis I/II disorders). Participants were assessed with the Cambridge Depersonalization Scales, the Temperament and Character Inventory, and the Panic and Agoraphobia Scale. RESULTS Forty-eight percent of the sample had depersonalization symptoms during the panic attack, whereas 20% of patients had a depersonalization disorder. Women presented more depersonalization disorders than did men (P = .036). Patients with panic disorder with depersonalization disorder had a more severe panic disorder (P = .002). Logistic regression analysis showed that self-transcendence trait (odds ratio, 1.089; 95% confidence interval, 1.021-1.162; P = .010) and severity of panic (odds ratio, 1.056; 95% confidence interval, 1.005-1.110; P = .032) were independently associated with depersonalization disorder. CONCLUSIONS A high prevalence of depersonalization symptoms and depersonalization disorder was confirmed in patients with panic disorder, supporting a dosage effect model for understanding depersonalization pathology. Self-transcendence trait and severity of panic disorder were reported as risk factors for depersonalization disorder.
Collapse
Affiliation(s)
- Lilian Mendoza
- Institute of Neuroscience, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigación Biomédica en Red de Salud Mental, University of Barcelona, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Albacar G, Sans T, Martín-Santos R, García-Esteve L, Guillamat R, Sanjuan J, Cañellas F, Gratacòs M, Cavalle P, Arija V, Gaviria A, Gutiérrez-Zotes A, Vilella E. An association between plasma ferritin concentrations measured 48 h after delivery and postpartum depression. J Affect Disord 2011; 131:136-42. [PMID: 21130499 DOI: 10.1016/j.jad.2010.11.006] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/06/2010] [Revised: 11/05/2010] [Accepted: 11/05/2010] [Indexed: 01/01/2023]
Abstract
CONTEXT Iron deficiency is the most common nutritional problem experienced by childbearing women, and postpartum depression (PPD) is the most common psychiatric disorder seen during the first year after delivery. The possible link between iron deficiency and PPD is not clear. OBJECTIVE To evaluate whether iron status 48 h after delivery was associated with PPD. Our hypothesis was that iron deficiency would be associated with PPD. DESIGN This was a prospective cohort study of depression-free women studied in the postpartum period. SETTING Women who give birth at obstetric units in several general hospitals in Spain. PARTICIPANTS A subsample of 729 women was included in the present study after exclusion of women with high C-reactive protein (CRP) and other diseases known to interfere with iron metabolism. MAIN OUTCOME MEASURES We evaluated depressive symptoms at 48 h, 8 weeks and 32 weeks postpartum and used a diagnostic interview to confirm the diagnosis of major depression. A blood sample obtained 48 h after delivery was used to measure the following iron storage parameters: ferritin, transferrin (Tf), free iron and transferrin saturation (TfS) and the inflammatory marker CCRP. RESULTS Overall, the women in the study had low iron concentrations (8.8 ± 6.9 μmol/L) and low TfS (12.6 ± 9.6%) but normal ferritin and Tf concentrations. A total of 65 women (9%) developed PPD during the 32 week postpartum period; these women also had a lower ferritin concentration (15.4 ± 12.7 μg/L vs. 21.6 ± 13.5 μg/L, P = 0.002). A strong association between ferritin and PPD was observed (odds ratio = 3.73, 95% CI: 1.84-7.56; P = 0.0001 for ferritin cutoff value of 7.26 μg/L). In our study, ferritin concentrations have a high specificity but low sensitivity in predicting PPD. CONCLUSIONS These findings support the role of iron in the etiology of PPD and the use of ferritin as a marker of iron deficiency in the postpartum period. We believe that this topic deserves further investigation.
Collapse
Affiliation(s)
- Glòria Albacar
- Hospital Psiquiàtric Universitari Institut Pere Mata, IISPV, Universitat Rovira i Virgili, Reus, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Gelabert E, Subirà S, Plaza A, Torres A, Navarro P, Imaz ML, Valdés M, García-Esteve L, Martín-Santos R. The Vulnerable Personality Style Questionnaire: psychometric properties in Spanish postpartum women. Arch Womens Ment Health 2011; 14:115-24. [PMID: 21052750 DOI: 10.1007/s00737-010-0186-y] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/11/2010] [Accepted: 09/09/2010] [Indexed: 01/03/2023]
Abstract
The Vulnerable Personality Style Questionnaire (VPSQ) is a nine-item self-report scale developed to asses personality traits which increase the risk of postpartum depression. The aim of the present study was to examine the psychometric properties of the Spanish version of the VPSQ in a sample of postpartum women. A cohort of 309 postpartum women was followed up for 32 weeks after delivery. All women were assessed with the Spanish version of the VPSQ, the Eysenck Personality Questionnaire-R Short Scale, the Frost Multidimensional Perfectionism Scale and the harm avoidance dimension of the Temperament and Character Inventory at 2-3 days postpartum. Depressive symptoms were evaluated at 8 and 32 weeks after delivery by the Edinburgh Postnatal Depression Scale, and a diagnostic interview was used to confirm the presence of major depression disorder. Factor analysis results revealed the unidimensionality of the Spanish version of the VPSQ. Cronbach's alpha coefficient for the VPSQ total score was 0.63. The test-retest reliability indicated a good temporal stability (ICC = 0.88; 95% confidence interval (CI) = 0.82-0.91). A moderate association between the VPSQ and other personality measures provided evidence for its construct validity. Logistic regression analyses showed that women with higher scores on the VPSQ had a higher risk of developing depressive symptoms (OR = 1.20; 95% CI = 1.11-1.29) and major depression (OR = 1.16; 95% CI = 1.07-1.26) throughout the 32 weeks after delivery. Overall, our results suggest adequate psychometric properties of the Spanish version of the VPSQ and its usefulness in identifying women with a personality style that increases the risk of developing postpartum depression.
Collapse
Affiliation(s)
- Estel Gelabert
- Neurospychopharmacology Programme, IMIM-Hospital del Mar, Barcelona, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Diez-Quevedo C, Masnou H, Planas R, Castellví P, Giménez D, Morillas RM, Martín-Santos R, Navinés R, Solà R, Giner P, Ardèvol M, Costa J, Diago M, Pretel J. Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011; 72:522-8. [PMID: 21034680 DOI: 10.4088/jcp.09m05282blu] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/03/2009] [Accepted: 10/19/2009] [Indexed: 12/17/2022]
Abstract
BACKGROUND Depression is one of the main reasons for treatment withdrawal and failure in chronic hepatitis C patients treated with interferon. Antidepressants are useful for its treatment, but whether they can also be used for prevention has yet to be established. METHOD To evaluate the efficacy and safety of escitalopram for preventing interferon alfa-2a-induced depression, we conducted an investigator-initiated multicenter, randomized, double-blind, placebo-controlled trial in 133 chronic hepatitis C patients without baseline mental disorders who were randomly assigned to receive escitalopram or placebo during the first 12 weeks of treatment. Primary efficacy outcomes were the development of DSM-IV major depression and scores on the Montgomery-Asberg Depression Rating Scale (MADRS) and the Hospital Anxiety and Depression Scale (HADS). Primary safety end points were biochemical and virological responses. Patients were recruited between March 2005 and July 2006. RESULTS Rates of major depression were low (5.4%) and did not differ between placebo (3.2%) and escitalopram (7.6%). MADRS and HADS scores significantly increased during treatment (P < .001 and P = .028, respectively), but there were no differences between treatment groups. Sustained virological response was achieved by 69.2% of patients, 70.4% in the placebo group and 67.9% in the escitalopram group. CONCLUSIONS Findings do not support the use of an antidepressant to prevent interferon-induced depression during the first 12 weeks of treatment in chronic hepatitis C patients at low psychiatric risk. Future studies should be directed to subpopulations of patients at high psychiatric risk. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00166296.
Collapse
Affiliation(s)
- Crisanto Diez-Quevedo
- Department of Psychiatry, Hospital Universitari Germans Trias i Pujol, Autonomous University of Barcelona, Ctra de Canyet s/n, 08916 Badalona, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Muiños-Gimeno M, Espinosa-Parrilla Y, Guidi M, Kagerbauer B, Sipilä T, Maron E, Pettai K, Kananen L, Navinés R, Martín-Santos R, Gratacòs M, Metspalu A, Hovatta I, Estivill X. Human microRNAs miR-22, miR-138-2, miR-148a, and miR-488 are associated with panic disorder and regulate several anxiety candidate genes and related pathways. Biol Psychiatry 2011; 69:526-33. [PMID: 21168126 DOI: 10.1016/j.biopsych.2010.10.010] [Citation(s) in RCA: 138] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2010] [Revised: 08/24/2010] [Accepted: 10/07/2010] [Indexed: 01/04/2023]
Abstract
BACKGROUND The involvement of microRNAs (miRNAs) in neuronal differentiation and synaptic plasticity suggests a role for miRNAs in psychiatric disorders; association analyses and functional approaches were used to evaluate the implication of miRNAs in the susceptibility for panic disorder. METHODS Case-control studies for 712 single-nucleotide polymorphisms (SNPs) tagging 325 human miRNA regions were performed in 203 Spanish patients with panic disorder and 341 control subjects. A sample of 321 anxiety patients and 642 control subjects from Finland and 102 panic disorder patients and 829 control subjects from Estonia was used as a replica. Reporter-gene assays and miRNA overexpression experiments in neuroblastoma cells were used to functionally evaluate the spectrum of genes regulated by the associated miRNAs. RESULTS Two SNPs associated with panic disorder: rs6502892 tagging miR-22 (p < .0002), and rs11763020 tagging miR-339 (p < .00008). Other SNPs tagging miR-138-2, miR-488, miR-491, and miR-148a regions associated with different panic disorder phenotypes. Replication in the north-European sample supported several of these associations, although they did not pass correction for multiple testing. Functional studies revealed that miR-138-2, miR-148a, and miR-488 repress (30%-60%) several candidate genes for panic disorder--GABRA6, CCKBR and POMC, respectively--and that miR-22 regulates four other candidate genes: BDNF, HTR2C, MAOA, and RGS2. Transcriptome analysis of neuroblastoma cells transfected with miR-22 and miR-488 showed altered expression of a subset of predicted target genes for these miRNAs and of genes that might be affecting physiological pathways related to anxiety. CONCLUSIONS This work represents the first report of a possible implication of miRNAs in the etiology of panic disorder.
Collapse
Affiliation(s)
- Margarita Muiños-Gimeno
- Genes and Disease Program, Centre for Genomic Regulation (CRG), Public Health and Epidemiology Network Biomedical Research Center (CIBERESP), Barcelona, Catalonia, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Gelabert E, Subirà S, Garcia-Esteve L, Navarro P, Plaza A, Cuyàs E, Martín-Santos R. Perfectionism and other risk factors in postpartum depression: a case-control study. Eur Psychiatry 2011. [DOI: 10.1016/s0924-9338(11)72800-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
IntroductionAlthough perfectionism has generally been associated with depressive illness in general, there are no studies on its role in major depression in the postnatal period. The aim of the present study was to explore the relationship between perfectionism and major postpartum depression.MethodsIn this case-control study, we compared the differences in perfectionism dimensions between 122 women with major postpartum depression (SCID-I; DSM-IV) and 115 healthy postpartum women. The Frost Multidimensional Perfectionism Scale (FMPS) was used to assess perfectionism. Other variables were also considered: Socio-demographic and obstetric data, psychiatric history, other personality traits, social support, life events and genotype combinations according to serotonin transporter expression (5-HTTLPR and Stin2 VNTR polymorphisms).ResultsMultivariate models confirmed perfectionism as an independent factor associated with major postpartum depression. The FMPS dimension concern over mistakes was associated with a 4-fold increase in risk for major postpartum depression (OR = 4.14; 95%CI: 1.24–13.81). Neuroticism, personal psychiatric history and 5-HTT low-expressing genotypes at one of the loci were also identified as independent factors.ConclusionsPerfectionism, and particularly the concern over mistakes perfectionism dimension, is associated with major postpartum depression. These results highlight the importance of assessing personality traits together with other risk factors to identify women at risk of depression after childbirth.
Collapse
|